Funding verdicts by country

NHS coverage →US coverage and assistance →

539 appraisal verdicts for 296 products across 4 bodies: NICE 288, G-BA 122, PBAC 6, SMC 123. Regulatory approval says a medicine may be sold; a health technology assessment says whether a health system will pay for it, for whom, and at what price. Dates and links go to the appraisal itself.

Being re-checked

4 NICE pages do not name the product they are cited for, or say the guidance was withdrawn or replaced: Tremelimumab, Letrozole (and other aromatase inhibitors), Enfortumab vedotin, Glasdegib. Treat these rows as provisional until the appraisal reference is confirmed; if you know the correct appraisal, tell us through the issue form.

539 verdicts

				Appraisal
2026-09-16	Mirdametinib Gomekli / Ezmekly · Small-molecule allosteric MEK1/2 inhibitor	NICEUK	Recommended (optimised)	Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 yearsSymptomatic, inoperable NF1 plexiform neurofibromas in people aged 2 to 17, using the least expensive suitable MEK inhibitor
2026-09-15	Nogapendekin alfa inbakicept Anktiva · IL-15 superagonist (intravesical, with BCG)	G-BAGermany	Procedure started	Nogapendekin alfa inbakicept (BCG-unresponsives nicht-muskelinvasives Blasenkarzinom (NMIBC), in Kombination mit Bacillus Calmette-Guérin (BCG))BCG-unresponsives nicht-muskelinvasives Blasenkarzinom (NMIBC), in Kombination mit Bacillus Calmette-Guérin (BCG)
2026-09-01	Datopotamab deruxtecan Datroway · ADC	G-BAGermany	Procedure started	Datopotamab deruxtecan (Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie)Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie
2026-09-01	Mavorixafor Xolremdi · Oral CXCR4 antagonist	G-BAGermany	Procedure started	Mavorixafor (WHIM-Syndrom (Warzen-Hypogammaglobulinämie-Immundefizienz-Myelokathexis-Syndrom))WHIM-Syndrom (Warzen-Hypogammaglobulinämie-Immundefizienz-Myelokathexis-Syndrom)
2026-09-01	Pirtobrutinib Jaypirca · Small-molecule non-covalent (reversible) BTK inhibitor	G-BAGermany	Procedure started	Pirtobrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), Monotherapie)Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), Monotherapie
2026-08-26	Dostarlimab Jemperli · Monoclonal antibody (anti-PD-1)	NICEUK	Recommended (optimised)	Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencydMMR/MSI-H advanced or recurrent endometrial cancer after platinum chemotherapy, stopped after 3 years
2026-08-01	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	G-BAGermany	Procedure started	Durvalumab (Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie)Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie
2026-08-01	Enfortumab vedotin Padcev · ADC	G-BAGermany	Procedure started	Enfortumab Vedotin (Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom, neoadjuvante/adjuvante Therapie nach Zystektomie, in Kombination mit Pembrolizumab)Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom, neoadjuvante/adjuvante Therapie nach Zystektomie, in Kombination mit Pembrolizumab
2026-08-01	Sacituzumab govitecan Trodelvy · ADC	G-BAGermany	Procedure started	Sacituzumab govitecan (Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie)Neues Anwendungsgebiet: Mammakarzinom, triple-negativ, Erstlinie
2026-08-01	Serplulimab Hetronifly · Monoclonal antibody (anti-PD-1)	G-BAGermany	Procedure started	Serplulimab (Aufhebung des regulatorischen Orphanstatus: Kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie)Aufhebung des regulatorischen Orphanstatus: Kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie
2026-08-01	Serplulimab Hetronifly · Monoclonal antibody (anti-PD-1)	G-BAGermany	Procedure started	Serplulimab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, nicht-plattenepithelial, EGFR-, ALK- und ROS-negativ, Erstlinie, Kombination mit Carboplatin und Pemetrexed)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, nicht-plattenepithelial, EGFR-, ALK- und ROS-negativ, Erstlinie, Kombination mit Carboplatin und Pemetrexed
2026-08-01	Serplulimab Hetronifly · Monoclonal antibody (anti-PD-1)	G-BAGermany	Procedure started	Serplulimab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, plattenepithelial, Erstlinie, Kombination mit Carboplatin und Nab-Paclitaxel)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, plattenepithelial, Erstlinie, Kombination mit Carboplatin und Nab-Paclitaxel
2026-08-01	Serplulimab Hetronifly · Monoclonal antibody (anti-PD-1)	G-BAGermany	Procedure started	Serplulimab (Neues Anwendungsgebiet: Plattenepithelkarzinom des Ösophagus, PD-L1 mit CPS ≥ 5, Erstlinie, Kombination mit einer Fluoropyrimidin- und platinbasierten Chemotherapie)Neues Anwendungsgebiet: Plattenepithelkarzinom des Ösophagus, PD-L1 mit CPS ≥ 5, Erstlinie, Kombination mit einer Fluoropyrimidin- und platinbasierten Chemotherapie
2026-07-15	Encorafenib Braftovi · Small-molecule kinase inhibitor (BRAF)	G-BAGermany	Procedure started	Encorafenib (Neues Anwendungsgebiet: Kolorektalkarzinom mit BRAF-V600E-Mutation; Erstlinie; Kombination mit Cetuximab und FOLFOX)Neues Anwendungsgebiet: Kolorektalkarzinom mit BRAF-V600E-Mutation; Erstlinie; Kombination mit Cetuximab und FOLFOX
2026-07-15	Epcoritamab Tepkinly · Bispecific T-cell engager (CD20×CD3)	G-BAGermany	Procedure started	Epcoritamab (Neues Anwendungsgebiet: Follikuläres Lymphom, rezidiviert oder refraktär, in Kombination mit Lenalidomid und Rituximab)Neues Anwendungsgebiet: Follikuläres Lymphom, rezidiviert oder refraktär, in Kombination mit Lenalidomid und Rituximab
2026-07-01	Burosumab Crysvita · Monoclonal antibody (anti-FGF23)	G-BAGermany	Stellungnahmeverfahren eröffnet	Burosumab (Neues Anwendungsgebiet: X-chromosomale Hypophosphatämie; ≥ 1 Monat bis < 1 Jahr)Neues Anwendungsgebiet: X-chromosomale Hypophosphatämie; ≥ 1 Monat bis < 1 Jahr
2026-07-01	Lurbinectedin Zepzelca · Cytotoxic (transcription inhibitor)	G-BAGermany	Stellungnahmeverfahren eröffnet	Lurbinectedin (Kleinzelliges Lungenkarzinom, extensives Stadium, Erhaltungstherapie, Kombination mit Atezolizumab)Kleinzelliges Lungenkarzinom, extensives Stadium, Erhaltungstherapie, Kombination mit Atezolizumab
2026-07-01	Pirtobrutinib Jaypirca · Small-molecule non-covalent (reversible) BTK inhibitor	NICEUK	Recommended (optimised)	Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitorRelapsed or refractory CLL after a BTK inhibitor, only when retreatment with a covalent BTK inhibitor is not clinically appropriate
2026-07-01	Tarlatamab Imdylltra · Bispecific T-cell engager (DLL3×CD3)	G-BAGermany	Stellungnahmeverfahren eröffnet	Tarlatamab (fortgeschrittenes kleinzelliges Lungenkarzinom, vorbehandelt)fortgeschrittenes kleinzelliges Lungenkarzinom, vorbehandelt
2026-07-01	Venetoclax Venclyxto · Small-molecule BCL-2 inhibitor	G-BAGermany	Stellungnahmeverfahren eröffnet	Venetoclax (Neues Anwendungsgebiet: chronische lymphatische Leukämie, Erstlinie, Kombination mit Acalabrutinib mit oder ohne Obinutuzumab)Neues Anwendungsgebiet: chronische lymphatische Leukämie, Erstlinie, Kombination mit Acalabrutinib mit oder ohne Obinutuzumab
2026-07-01	Venetoclax Venclyxto · Small-molecule BCL-2 inhibitor	G-BAGermany	Stellungnahmeverfahren eröffnet	Venetoclax (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Ibrutinib)Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Ibrutinib
2026-07	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – July 2026 documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2026-06-24	Mirvetuximab soravtansine Elahere · ADC	NICEUK	Recommended	Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancerFolate receptor-alpha-positive, platinum-resistant high-grade serous ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 lines of systemic treatment
2026-06-18	Serplulimab Hansizhuang / Hetronifly · Monoclonal antibody (anti-PD-1)	NICEUK	Recommended	Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerWith carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
2026-06-15	Dorocubicel (UM171-expanded cord blood) Zemcelpro · Allogeneic expanded cord blood cell therapy (ATMP)	G-BAGermany	Stellungnahmeverfahren eröffnet	Dorocubicel / nicht-expandierte allogene CD34-Zellen aus der Nabelschnur (Hämatologische Malignitäten, allogene hämatopoetische Stammzelltransplantation angezeigt, keine Spende verfügbar)Hämatologische Malignitäten, allogene hämatopoetische Stammzelltransplantation angezeigt, keine Spende verfügbar
2026-06-15	Selpercatinib Retsevmo · Small-molecule kinase inhibitor (RET)	G-BAGermany	Stellungnahmeverfahren eröffnet	Selpercatinib (Neues Anwendungsgebiet: RET-mutiertes medulläres Schilddrüsenkarzinom (MTC), ≥ 2 Jahre)Neues Anwendungsgebiet: RET-mutiertes medulläres Schilddrüsenkarzinom (MTC), ≥ 2 Jahre
2026-06-15	Selpercatinib Retsevmo · Small-molecule kinase inhibitor (RET)	G-BAGermany	Stellungnahmeverfahren eröffnet	Selpercatinib (Neues Anwendungsgebiet: Schilddrüsenkarzinom, RET-Fusions+, refraktär für radioaktives Iod, ≥ 2 Jahre)Neues Anwendungsgebiet: Schilddrüsenkarzinom, RET-Fusions+, refraktär für radioaktives Iod, ≥ 2 Jahre
2026-06-15	Selpercatinib Retsevmo · Small-molecule kinase inhibitor (RET)	G-BAGermany	Stellungnahmeverfahren eröffnet	Selpercatinib (Neues Anwendungsgebiet: Solide Tumore, RET-Fusion+, ≥ 2 bis < 18 Jahre)Neues Anwendungsgebiet: Solide Tumore, RET-Fusion+, ≥ 2 bis < 18 Jahre
2026-06-11	Tisotumab vedotin Tivdak · ADC	NICEUK	Recommended	Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentRecurrent or metastatic cervical cancer that has progressed on or after systemic treatment
2026-06-01	Asciminib Scemblix · Small-molecule allosteric ABL1 inhibitor (STAMP)	G-BAGermany	Beschlussfassung wird vorbereitet	Asciminib (Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, CML-CP mit T315I-Mutation, vorbehandelt)Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, CML-CP mit T315I-Mutation, vorbehandelt
2026-06-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Beschlussfassung wird vorbereitet	Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, CD19+, rezidiviert oder refraktär, Erwachsene)Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, CD19+, rezidiviert oder refraktär, Erwachsene
2026-06-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Beschlussfassung wird vorbereitet	Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, Hochrisiko-Erstrezidiv, Kinder ab ≥1 Monat)Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, Hochrisiko-Erstrezidiv, Kinder ab ≥1 Monat
2026-06-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Beschlussfassung wird vorbereitet	Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, MRD-positiv, Erwachsene)Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, MRD-positiv, Erwachsene
2026-06-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Beschlussfassung wird vorbereitet	Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert, Erwachsene)Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert, Erwachsene
2026-06-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Beschlussfassung wird vorbereitet	Blinatumomab (Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, rezidiviert / refraktär, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation, Kinder ≥ 1 Monat)Neubewertung Orphan > 30 Mio: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, rezidiviert / refraktär, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation, Kinder ≥ 1 Monat
2026-06-01	Inotuzumab ozogamicin Besponsa · ADC	G-BAGermany	Beschlussfassung wird vorbereitet	Inotuzumab ozogamicin (Neues Anwendungsgebiet: akute lymphatische Vorläufer B-Zell-Leukämie, rezidiviert/refraktär, nach allogener Stammzelltransplantation oder nach Rezidiv mit sehr hohem Risiko oder nach ≥ 2 Vortherapien, CD22+, pädiatrische Patienten ≥ 1 Jahr)Neues Anwendungsgebiet: akute lymphatische Vorläufer B-Zell-Leukämie, rezidiviert/refraktär, nach allogener Stammzelltransplantation oder nach Rezidiv mit sehr hohem Risiko oder nach ≥ 2 Vortherapien, CD22+, pädiatrische Patienten ≥ 1 Jahr
2026-06-01	Relatlimab + nivolumab Opdualag · Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)	G-BAGermany	Beschlussfassung wird vorbereitet	Nivolumab/Relatlimab (Melanom, PD-L1-Expression < 1 %, fortgeschritten, Erstlinie, ≥ 12 Jahre)Melanom, PD-L1-Expression < 1 %, fortgeschritten, Erstlinie, ≥ 12 Jahre
2026-05-15	Tovorafenib Ojemda · Small-molecule type II RAF inhibitor	G-BAGermany	Beschlussfassung wird vorbereitet	Tovorafenib (Malignes Gliom, niedrig-gradig mit BRAF-Fusion oder -Umlagerung oder BRAF-V600-Mutation, nach mind. 1 Vortherapie, ≥ 6 Monate)Malignes Gliom, niedrig-gradig mit BRAF-Fusion oder -Umlagerung oder BRAF-V600-Mutation, nach mind. 1 Vortherapie, ≥ 6 Monate
2026-05-15	Zolbetuximab Vyloy · Monoclonal antibody (anti-Claudin 18.2)	G-BAGermany	Beschlussfassung wird vorbereitet	Zolbetuximab (Neubewertung Orphan > 30 Mio: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-negativ, Erstlinie, Kombination mit fluoropyrimidin- und platinhaltiger Chemotherapie)Neubewertung Orphan > 30 Mio: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2-negativ, Erstlinie, Kombination mit fluoropyrimidin- und platinhaltiger Chemotherapie
2026-05-07	Zanidatamab Ziihera · Biparatopic bispecific antibody (HER2)	NICEUK	Recommended	Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentHER2-positive (IHC3) unresectable or metastatic biliary tract cancer after at least 1 line of systemic treatment
2026-05-01	Belumosudil Rezurock · Oral ROCK2 inhibitor	G-BAGermany	Beschlussfassung wird vorbereitet	Belumosudil (Chronische Graft-versus-Host-Erkrankung (cGvHD), ≥ 12 Jahre, ≥ 40 kg)Chronische Graft-versus-Host-Erkrankung (cGvHD), ≥ 12 Jahre, ≥ 40 kg
2026-05	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – May 2026 Intracycle meeting documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2026-04-30	Belantamab mafodotin Blenrep · ADC	NICEUK	Recommended	Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myelomaWith bortezomib and dexamethasone for previously treated multiple myeloma (DREAMM-7)
2026-04-29	Vorasidenib Voranigo · Small-molecule IDH1/2 inhibitor	NICEUK	Recommended	Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and overIDH-mutant grade 2 astrocytoma or oligodendroglioma after surgery (INDIGO)
2026-04-28	Ripretinib Qinlock · Small-molecule kinase inhibitor (KIT/PDGFRA switch-control)	NICEUK	Recommended	Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitorsAdvanced GIST after 3 or more kinase inhibitors including imatinib
2026-04-01	Belantamab mafodotin Blenrep · ADC	G-BAGermany	Beschlussfassung wird vorbereitet	Belantamab-Mafodotin (Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Bortezomib und Dexamethason)Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Bortezomib und Dexamethason
2026-04-01	Belantamab mafodotin Blenrep · ADC	G-BAGermany	Beschlussfassung wird vorbereitet	Belantamab-Mafodotin (Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Pomalidomid und Dexamethason)Multiples Myelom, rezidiviert oder refraktär, nach mind. einer Vortherapie, Kombination mit Pomalidomid und Dexamethason
2026-04-01	Retifanlimab Zynyz · Anti-PD-1 monoclonal antibody (IgG4)	G-BAGermany	Beschlussfassung wird vorbereitet	Retifanlimab (Merkelzellkarzinom, metastasiert oder rezidiviert, Monotherapie, Erstlinie)Merkelzellkarzinom, metastasiert oder rezidiviert, Monotherapie, Erstlinie
2026-04-01	Retifanlimab Zynyz · Anti-PD-1 monoclonal antibody (IgG4)	G-BAGermany	Beschlussfassung wird vorbereitet	Retifanlimab (Neues Anwendungsgebiet: Plattenepithelkarzinom des Analkanals; Erstlinie)Neues Anwendungsgebiet: Plattenepithelkarzinom des Analkanals; Erstlinie
2026-03-15	Imlunestrant Inluriyo · Oral SERD	G-BAGermany	Verfahren abgeschlossen	Imlunestrant (Mammakarzinom, ER+, HER2-, mit ESR1-Mutation, progredient nach einer endokrinen Vortherapie)Mammakarzinom, ER+, HER2-, mit ESR1-Mutation, progredient nach einer endokrinen Vortherapie
2026-03-15	Niraparib Akeega · Small-molecule PARP inhibitor	G-BAGermany	Verfahren abgeschlossen	Niraparib/Abirateronacetat (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, BRCA1/2-Mutationen, Kombination mit Prednis(ol)on und Androgendeprivationstherapie)Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, BRCA1/2-Mutationen, Kombination mit Prednis(ol)on und Androgendeprivationstherapie
2026-03-01	Abemaciclib Verzenios · Small-molecule CDK4/6 inhibitor	G-BAGermany	Verfahren abgeschlossen	Abemaciclib (Neubewertung nach Fristablauf: Mammakarzinom, HR+, HER2-, früh mit hohem Rezidivrisiko, Adjuvanz, Kombination mit endokriner Therapie)Neubewertung nach Fristablauf: Mammakarzinom, HR+, HER2-, früh mit hohem Rezidivrisiko, Adjuvanz, Kombination mit endokriner Therapie
2026-03-01	Ivosidenib Tibsovo · Small-molecule IDH1 inhibitor	G-BAGermany	Verfahren abgeschlossen	Ivosidenib (Neubewertung Orphan > 30 Mio: Akute Myeloische Leukämie mit IDH1-R132-Mutation, Erstlinie, Kombination mit Azacitidin)Neubewertung Orphan > 30 Mio: Akute Myeloische Leukämie mit IDH1-R132-Mutation, Erstlinie, Kombination mit Azacitidin
2026-03-01	Ivosidenib Tibsovo · Small-molecule IDH1 inhibitor	G-BAGermany	Verfahren abgeschlossen	Ivosidenib (Neubewertung Orphan > 30 Mio: Cholangiokarzinom mit IDH1-R132-Mutation, nach mind. 1 Vortherapie)Neubewertung Orphan > 30 Mio: Cholangiokarzinom mit IDH1-R132-Mutation, nach mind. 1 Vortherapie
2026-03	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – March 2026 documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2026-02-25	Bevacizumab Avastin (and biosimilars) · Monoclonal antibody (anti-VEGF)	NICEUK	Recommended (optimised)	Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancerFirst- and second-line metastatic colorectal cancer, only when targeted treatments or immunotherapy are unsuitable and chemotherapy would otherwise be offered
2026-02-15	Selumetinib Koselugo · Small-molecule allosteric MEK1/2 inhibitor	G-BAGermany	Verfahren abgeschlossen	Selumetinib (Neues Anwendungsgebiet: Neurofibromatose Typ 1 (≥ 1 bis < 3 Jahre))Neues Anwendungsgebiet: Neurofibromatose Typ 1 (≥ 1 bis < 3 Jahre)
2026-02-15	Zanidatamab Ziihera · Biparatopic bispecific antibody (HER2)	G-BAGermany	Verfahren abgeschlossen	Zanidatamab (Biliäres Karzinom, HER2+ (IHC3+), vorbehandelt)Biliäres Karzinom, HER2+ (IHC3+), vorbehandelt
2026-02-01	Mirvetuximab soravtansine Elahere · ADC	G-BAGermany	Verfahren abgeschlossen	Mirvetuximab-Soravtansin (Neubewertung Orphan > 30 Mio: Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, FRα-positiv, platinresistent, nach 1 bis 3 Vortherapien)Neubewertung Orphan > 30 Mio: Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom, FRα-positiv, platinresistent, nach 1 bis 3 Vortherapien
2026-01-21	Amivantamab Rybrevant · Bispecific antibody (EGFR×MET)	NICEUK	Recommended	Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerWith lazertinib for untreated EGFR exon 19 deletion or exon 21 L858R advanced NSCLC
2026-01-21	Lazertinib Lazcluze · Small-molecule kinase inhibitor (EGFR)	NICEUK	Recommended	Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerWith amivantamab for untreated EGFR exon 19 deletion or exon 21 L858R advanced NSCLC
2026-01-15	Tafasitamab Minjuvi · Monoclonal antibody (anti-CD19, Fc-enhanced)	G-BAGermany	Verfahren abgeschlossen	Tafasitamab (Neues Anwendungsgebiet: Follikuläres Lymphom, nach ≥ 1 Vortherapie, Kombination mit Lenalidomid und Rituximab)Neues Anwendungsgebiet: Follikuläres Lymphom, nach ≥ 1 Vortherapie, Kombination mit Lenalidomid und Rituximab
2026-01-15	Toripalimab Loqtorzi · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Toripalimab (Plattenepithelkarzinom des Ösophagus, Erstlinie, Kombination mit Cisplatin und Paclitaxel)Plattenepithelkarzinom des Ösophagus, Erstlinie, Kombination mit Cisplatin und Paclitaxel
2026-01-15	Toripalimab Loqtorzi · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Toripalimab (Rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Cisplatin und Gemcitabin)Rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Cisplatin und Gemcitabin
2026-01-01	Selpercatinib Retsevmo · Small-molecule kinase inhibitor (RET)	G-BAGermany	Verfahren abgeschlossen	Selpercatinib (Neubewertung nach Fristablauf: Nicht-kleinzelliges Lungenkarzinom, RET-Fusion+, Erstlinie)Neubewertung nach Fristablauf: Nicht-kleinzelliges Lungenkarzinom, RET-Fusion+, Erstlinie
2026	Imlunestrant Inluriyo · Oral SERD	NICEUK	Terminated	Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)ER-positive HER2-negative advanced breast cancer after endocrine therapy
2026	Nogapendekin alfa inbakicept Anktiva · IL-15 superagonist (intravesical, with BCG)	NICEUK	Terminated	Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)With BCG for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ
2025-12-15	Cemiplimab Libtayo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Cemiplimab (Neues Anwendungsgebiet: kutanes Plattenepithelkarzinom, nach Resektion und Strahlentherapie, adjuvante Therapie)Neues Anwendungsgebiet: kutanes Plattenepithelkarzinom, nach Resektion und Strahlentherapie, adjuvante Therapie
2025-12-15	Lisocabtagene maraleucel Breyanzi · CAR-T (CD19, defined CD4:CD8)	G-BAGermany	Verfahren abgeschlossen	Lisocabtagen maraleucel (Neues Anwendungsgebiet: Mantelzell-Lymphom, nach ≥ 2 Vortherapien)Neues Anwendungsgebiet: Mantelzell-Lymphom, nach ≥ 2 Vortherapien
2025-12-15	Nivolumab Opdivo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Nivolumab (Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie)Neubewertung nach Fristablauf: Urothelkarzinom, PD-L1-Expression ≥ 1 %, adjuvante Therapie
2025-12-11	Obecabtagene autoleucel Aucatzyl · CAR-T (CD19, fast off-rate)	NICEUK	Recommended (optimised)	Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaRelapsed or refractory B-cell precursor ALL in people aged 26 and over
2025-12-03	Talquetamab Talvey · Bispecific T-cell engager (GPRC5D×CD3)	NICEUK	Recommended	Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsRelapsed and refractory multiple myeloma after 3 or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) that progressed on the last treatment
2025-12-01	Asciminib Scemblix · Small-molecule allosteric ABL1 inhibitor (STAMP)	G-BAGermany	Verfahren abgeschlossen	Asciminib (Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, chronische Phase)Neues Anwendungsgebiet: Chronische myeloische Leukämie, Ph+, chronische Phase
2025-12-01	Pembrolizumab Keytruda · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Pembrolizumab (Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie)Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie
2025-12	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – December 2025 Intracycle Meeting documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2025-11-15	Selumetinib Koselugo · Small-molecule allosteric MEK1/2 inhibitor	G-BAGermany	Verfahren abgeschlossen	Selumetinib (Neubewertung Orphan > 30 Mio: Neurofibromatose Typ 1 (≥ 3 bis < 18 Jahre))Neubewertung Orphan > 30 Mio: Neurofibromatose Typ 1 (≥ 3 bis < 18 Jahre)
2025-11-15	Selumetinib Koselugo · Small-molecule allosteric MEK1/2 inhibitor	G-BAGermany	Verfahren abgeschlossen	Selumetinib (Neues Anwendungsgebiet: Neurofibromatose Typ 1 (≥ 18 Jahre))Neues Anwendungsgebiet: Neurofibromatose Typ 1 (≥ 18 Jahre)
2025-11-15	Vorasidenib Voranigo · Small-molecule IDH1/2 inhibitor	G-BAGermany	Verfahren abgeschlossen	Vorasidenib (Astrozytom oder Oligodendrogliom, Grad 2, IDH1-R132- oder IDH2-R172-Mutation, nach chirurgischer Intervention, ≥ 12 Jahre ≥ 40 kg)Astrozytom oder Oligodendrogliom, Grad 2, IDH1-R132- oder IDH2-R172-Mutation, nach chirurgischer Intervention, ≥ 12 Jahre ≥ 40 kg
2025-11-01	Avapritinib Ayvakyt · Small-molecule kinase inhibitor (PDGFRA D842V / KIT)	G-BAGermany	Verfahren abgeschlossen	Avapritinib (Neubewertung Orphan > 30 Mio: fortgeschrittene systemische Mastozytose, nach mind. 1 Vortherapie)Neubewertung Orphan > 30 Mio: fortgeschrittene systemische Mastozytose, nach mind. 1 Vortherapie
2025-11-01	Avapritinib Ayvakyt · Small-molecule kinase inhibitor (PDGFRA D842V / KIT)	G-BAGermany	Verfahren abgeschlossen	Avapritinib (Neubewertung Orphan > 30 Mio: Gastrointestinale Stromatumoren)Neubewertung Orphan > 30 Mio: Gastrointestinale Stromatumoren
2025-11-01	Avapritinib Ayvakyt · Small-molecule kinase inhibitor (PDGFRA D842V / KIT)	G-BAGermany	Verfahren abgeschlossen	Avapritinib (Neubewertung Orphan > 30 Mio: Indolente systemische Mastozytose (ISM))Neubewertung Orphan > 30 Mio: Indolente systemische Mastozytose (ISM)
2025-11-01	Momelotinib Omjjara · Small-molecule JAK1/JAK2/ACVR1 inhibitor	G-BAGermany	Verfahren abgeschlossen	Momelotinib (Neubewertung Orphan > 30 Mio: Myelofibrose)Neubewertung Orphan > 30 Mio: Myelofibrose
2025-11-01	Vimseltinib Romvimza · Small-molecule kinase inhibitor (CSF1R)	G-BAGermany	Verfahren abgeschlossen	Vimseltinib (Symptomatische tenosynoviale Riesenzelltumoren)Symptomatische tenosynoviale Riesenzelltumoren
2025-11	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – November 2025 documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2025-10-15	Nirogacestat Ogsiveo · Small-molecule gamma-secretase inhibitor	G-BAGermany	Verfahren abgeschlossen	Nirogacestat (Desmoid-Tumor, fortgeschritten)Desmoid-Tumor, fortgeschritten
2025-10-01	Linvoseltamab Lynozyfic · Bispecific T-cell engager (BCMA×CD3)	G-BAGermany	Verfahren abgeschlossen	Linvoseltamab (Multiples Myelom, mind. 3 Vortherapien, Monotherapie)Multiples Myelom, mind. 3 Vortherapien, Monotherapie
2025-10-01	Mirdametinib Ezmekly · Small-molecule allosteric MEK1/2 inhibitor	G-BAGermany	Verfahren abgeschlossen	Mirdametinib (Plexiforme Neurofibrome (PN), Neurofibromatose Typ 1 (NF1); ≥ 2 Jahre)Plexiforme Neurofibrome (PN), Neurofibromatose Typ 1 (NF1); ≥ 2 Jahre
2025-10-01	Tislelizumab Tevimbra · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Tislelizumab (Neues Anwendungsgebiet: Kleinzelliges Lungenkarzinom, Erstlinie, Kombination mit Etoposid und Platin-Chemotherapie)Neues Anwendungsgebiet: Kleinzelliges Lungenkarzinom, Erstlinie, Kombination mit Etoposid und Platin-Chemotherapie
2025-10-01	Tislelizumab Tevimbra · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Tislelizumab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, hohes Rezidivrisiko, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, hohes Rezidivrisiko, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie
2025-10-01	Tislelizumab Tevimbra · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Tislelizumab (Neues Anwendungsgebiet: rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Gemcitabin and Cisplatin)Neues Anwendungsgebiet: rezidiviertes oder metastasiertes Nasopharynxkarzinom (NPC), Erstlinie, Kombination mit Gemcitabin and Cisplatin
2025-10-01	Trastuzumab deruxtecan Enhertu · ADC	G-BAGermany	Verfahren abgeschlossen	Trastuzumab deruxtecan (Neue wissenschaftliche Erkenntnisse § 14: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2+, nach Trastuzumab-basierter Therapie)Neue wissenschaftliche Erkenntnisse § 14: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, HER2+, nach Trastuzumab-basierter Therapie
2025-09-01	Tisotumab vedotin Tivdak · ADC	G-BAGermany	Verfahren abgeschlossen	Tisotumab vedotin (Zervixkarzinom, vorbehandelt)Zervixkarzinom, vorbehandelt
2025-09	All items considered at the meeting	PBACAustralia	Outcomes document	Recommendations made by the PBAC – September 2025 Intracycle meeting documentPBAC publishes outcomes as PDF; open the document for product-level recommendations.
2025-08-20	Tarlatamab Imdelltra · Bispecific T-cell engager (DLL3×CD3)	NICEUK	Not recommended	Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsExtensive-stage small cell lung cancer after 2 or more lines of treatment including platinum chemotherapy (DeLLphi-301)
2025-08-15	Daratumumab Darzalex · Monoclonal antibody (anti-CD38)	G-BAGermany	Verfahren abgeschlossen	Daratumumab (Neues Anwendungsgebiet: Multiples Myelom, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)Neues Anwendungsgebiet: Multiples Myelom, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason
2025-08-15	Daratumumab Darzalex · Monoclonal antibody (anti-CD38)	G-BAGermany	Verfahren abgeschlossen	Daratumumab (Neues Anwendungsgebiet: schwelendes multiples Myelom (SMM))Neues Anwendungsgebiet: schwelendes multiples Myelom (SMM)
2025-08-15	Darolutamide Nubeqa · Small-molecule AR antagonist	G-BAGermany	Verfahren abgeschlossen	Darolutamid (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, Kombination mit Androgendeprivationstherapie)Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, Kombination mit Androgendeprivationstherapie
2025-08-15	Inavolisib Itovebi · Small-molecule PI3Kα inhibitor and degrader	G-BAGermany	Verfahren abgeschlossen	Inavolisib (Mammakarzinom, PIK3CA-mutiert, ER+, HER2-, lokal fortgeschritten oder metastasiert, Rezidiv < 12 Monate nach adjuvanter endokriner Therapie, Kombination mit Palbociclib und Fulvestrant)Mammakarzinom, PIK3CA-mutiert, ER+, HER2-, lokal fortgeschritten oder metastasiert, Rezidiv < 12 Monate nach adjuvanter endokriner Therapie, Kombination mit Palbociclib und Fulvestrant
2025-08-15	Isatuximab Sarclisa · Monoclonal antibody (anti-CD38)	G-BAGermany	Verfahren abgeschlossen	Isatuximab (Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation geeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation geeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason
2025-08-01	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	G-BAGermany	Verfahren abgeschlossen	Durvalumab (Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie)Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie
2025-08-01	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	G-BAGermany	Verfahren abgeschlossen	Durvalumab (Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin)Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin
2025-08-01	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	G-BAGermany	Verfahren abgeschlossen	Durvalumab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie)Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie
2025-08-01	Odronextamab Ordspono · Bispecific T-cell engager (CD20×CD3)	G-BAGermany	Verfahren abgeschlossen	Odronextamab (Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien)Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien
2025-08-01	Odronextamab Ordspono · Bispecific T-cell engager (CD20×CD3)	G-BAGermany	Verfahren abgeschlossen	Odronextamab (follikuläres Lymphom, nach ≥ 2 Vortherapien)follikuläres Lymphom, nach ≥ 2 Vortherapien
2025-07-23	Fruquintinib Fruzaqla · Small-molecule kinase inhibitor (VEGFR1-3)	NICEUK	Recommended (optimised)	Fruquintinib for previously treated metastatic colorectal cancerThird-line or later metastatic colorectal cancer after fluoropyrimidine, oxaliplatin and irinotecan chemotherapy (and anti-EGFR treatment if RAS wild-type), only when trifluridine-tipiracil with bevacizumab is not suitable
2025-07-21	Sargramostim Imreplys · Recombinant granulocyte-macrophage colony-stimulating factor, injection	G-BAGermany	wurde freigestellt	Sargramostim
2025-07-15	Givinostat Duvyzat · small molecule	G-BAGermany	Verfahren abgeschlossen	Givinostat (Duchenne-Muskeldystrophie, ≥ 6 Jahre, Kombination mit einem Corticosteroid)Duchenne-Muskeldystrophie, ≥ 6 Jahre, Kombination mit einem Corticosteroid
2025-07-01	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	G-BAGermany	Verfahren abgeschlossen	Acalabrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax)Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax
2025-07-01	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	G-BAGermany	Verfahren abgeschlossen	Acalabrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax und Obinutuzumab)Neues Anwendungsgebiet: Chronische lymphatische Leukämie, Erstlinie, Kombination mit Venetoclax und Obinutuzumab
2025-07-01	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	G-BAGermany	Verfahren abgeschlossen	Acalabrutinib (Neues Anwendungsgebiet: Mantelzell-Lymphom, autologe Stammzelltransplantation ungeeignet, Erstlinie, Kombination mit Bendamustin und Rituximab)Neues Anwendungsgebiet: Mantelzell-Lymphom, autologe Stammzelltransplantation ungeeignet, Erstlinie, Kombination mit Bendamustin und Rituximab
2025-07-01	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	G-BAGermany	Verfahren abgeschlossen	Acalabrutinib (Neues Anwendungsgebiet: Mantelzell-Lymphom, keine BTKi Vortherapie, rezidiviert oder refraktär, Monotherapie)Neues Anwendungsgebiet: Mantelzell-Lymphom, keine BTKi Vortherapie, rezidiviert oder refraktär, Monotherapie
2025-07-01	Nivolumab Opdivo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Nivolumab (Neubewertung nach Fristablauf: Karzinom des Ösophagus oder gastroösophagealen Übergangs, vorbehandelte Patienten, adjuvante Therapie)Neubewertung nach Fristablauf: Karzinom des Ösophagus oder gastroösophagealen Übergangs, vorbehandelte Patienten, adjuvante Therapie
2025-06-15	Nivolumab Opdivo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Nivolumab (Neues Anwendungsgebiet: Kolorektalkarzinom mit MSI-H oder mit dMMR, Erstlinie, Kombination mit Ipilimumab)Neues Anwendungsgebiet: Kolorektalkarzinom mit MSI-H oder mit dMMR, Erstlinie, Kombination mit Ipilimumab
2025-06-15	Nivolumab Opdivo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Nivolumab (Neues Anwendungsgebiet: nicht resezierbares oder fortgeschrittenes Leberzellkarzinom, Erstlinie, Kombination mit Ipilimumab)Neues Anwendungsgebiet: nicht resezierbares oder fortgeschrittenes Leberzellkarzinom, Erstlinie, Kombination mit Ipilimumab
2025-06-15	Nivolumab Opdivo · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Nivolumab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie)Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Monotherapie oder Kombination mit Platin-basierter Chemotherapie
2025-06-01	Asciminib Scemblix · Small-molecule allosteric ABL1 inhibitor (STAMP)	G-BAGermany	Verfahren abgeschlossen	Asciminib (Neubewertung Orphan > 30 Mio: Chronische myeloische Leukämie, Ph+, nach ≥ 2 Vortherapien)Neubewertung Orphan > 30 Mio: Chronische myeloische Leukämie, Ph+, nach ≥ 2 Vortherapien
2025-06-01	Datopotamab deruxtecan Datroway · ADC	G-BAGermany	Verfahren abgeschlossen	Datopotamab deruxtecan (Mammakarzinom, HR+, HER2-, nach min. 1 Vortherapie)Mammakarzinom, HR+, HER2-, nach min. 1 Vortherapie
2025-06-01	Selpercatinib Retsevmo · Small-molecule kinase inhibitor (RET)	G-BAGermany	Verfahren abgeschlossen	Selpercatinib (Neubewertung nach Fristablauf: Schilddrüsenkarzinom, RET-mutiert, Monotherapie, ab 12 Jahren)Neubewertung nach Fristablauf: Schilddrüsenkarzinom, RET-mutiert, Monotherapie, ab 12 Jahren
2025-05-15	Capivasertib Truqap · Small-molecule AKT inhibitor	NICEUK	Recommended	Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatmentWith fulvestrant for HR-positive HER2-negative advanced breast cancer with PIK3CA, AKT1 or PTEN alterations after a CDK4/6 inhibitor plus an aromatase inhibitor
2025-05-15	Glofitamab Columvi · Bispecific T-cell engager (CD20×CD3, 2:1)	G-BAGermany	Verfahren abgeschlossen	Glofitamab (Aufhebung des regulatorischen Orphanstatus: Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien)Aufhebung des regulatorischen Orphanstatus: Diffus großzelliges B-Zell-Lymphom (DLBCL), nach ≥ 2 Vortherapien
2025-05-15	Glofitamab Columvi · Bispecific T-cell engager (CD20×CD3, 2:1)	G-BAGermany	Verfahren abgeschlossen	Glofitamab (Neues Anwendungsgebiet: Diffuses großzelliges B-Zell-Lymphom, rezidiviert oder refraktär, Kombination mit Gemcitabin und Oxaliplatin, autologe Stammzelltransplantation nicht geeignet)Neues Anwendungsgebiet: Diffuses großzelliges B-Zell-Lymphom, rezidiviert oder refraktär, Kombination mit Gemcitabin und Oxaliplatin, autologe Stammzelltransplantation nicht geeignet
2025-05-12	Erdafitinib Balversa · Small-molecule kinase inhibitor (pan-FGFR)	NICEUK	Recommended	Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorUnresectable or metastatic urothelial cancer with susceptible FGFR3 alterations after at least 1 line of treatment that included a PD-1 or PD-L1 inhibitor
2025-05-01	Bevacizumab Lytenava · Monoclonal antibody (anti-VEGF)	G-BAGermany	Verfahren abgeschlossen	Bevacizumab (Bekannter Wirkstoff mit neuem Unterlagenschutz: Neovaskuläre altersabhängige Makuladegeneration)Bekannter Wirkstoff mit neuem Unterlagenschutz: Neovaskuläre altersabhängige Makuladegeneration
2025-05-01	Pembrolizumab Keytruda · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Pembrolizumab (Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie)Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie
2025-05-01	Repotrectinib Augtyro · Small-molecule kinase inhibitor (ROS1 / NTRK)	G-BAGermany	Verfahren abgeschlossen	Repotrectinib (Nicht-kleinzelliges Lungenkarzinom, ROS1-positiv)Nicht-kleinzelliges Lungenkarzinom, ROS1-positiv
2025-05-01	Repotrectinib Augtyro · Small-molecule kinase inhibitor (ROS1 / NTRK)	G-BAGermany	Verfahren abgeschlossen	Repotrectinib (Solide Tumore, NTRK-Genfusion, ≥ 12 Jahre)Solide Tumore, NTRK-Genfusion, ≥ 12 Jahre
2025-05-01	Serplulimab Hetronifly · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Serplulimab (kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie)kleinzelliges Lungenkarzinom, in Kombination mit Carboplatin und Etoposid, Erstlinie
2025-05-01	Trastuzumab deruxtecan Enhertu · ADC	G-BAGermany	Verfahren abgeschlossen	Trastuzumab deruxtecan (Neues Anwendungsgebiet: Mammakarzinom, HR+, HER2-low oder -ultralow, nach mind. 1 endokrinen Therapie)Neues Anwendungsgebiet: Mammakarzinom, HR+, HER2-low oder -ultralow, nach mind. 1 endokrinen Therapie
2025-04-15	Lisocabtagene maraleucel Breyanzi · CAR-T (CD19, defined CD4:CD8)	G-BAGermany	Verfahren abgeschlossen	Lisocabtagen maraleucel (Neues Anwendungsgebiet: follikuläres Lymphom, nach ≥ 2 Vortherapien)Neues Anwendungsgebiet: follikuläres Lymphom, nach ≥ 2 Vortherapien
2025-04-15	Pirtobrutinib Jaypirca · Small-molecule non-covalent (reversible) BTK inhibitor	G-BAGermany	Verfahren abgeschlossen	Pirtobrutinib (Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), rezidiviert oder refraktär, Monotherapie)Neues Anwendungsgebiet: Chronische lymphatische Leukämie (CLL), rezidiviert oder refraktär, Monotherapie
2025-04-01	Belzutifan Welireg · Small-molecule HIF-2α inhibitor	G-BAGermany	Verfahren abgeschlossen	Belzutifan (Nierenzellkarzinom, fortgeschritten, nach ≥ 2 Vortherapien)Nierenzellkarzinom, fortgeschritten, nach ≥ 2 Vortherapien
2025-04-01	Belzutifan Welireg · Small-molecule HIF-2α inhibitor	G-BAGermany	Verfahren abgeschlossen	Belzutifan (Von Hippel-Lindau-Syndrom (VHL)-assoziierte Tumoren)Von Hippel-Lindau-Syndrom (VHL)-assoziierte Tumoren
2025-03-26	Lisocabtagene maraleucel Breyanzi · CAR-T (CD19, defined CD4:CD8)	NICEUK	Recommended	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableLarge B-cell lymphoma refractory to, or relapsed within 12 months of, first-line chemoimmunotherapy when an autologous stem cell transplant would be suitable
2025-03-12	Zolbetuximab Vyloy · Monoclonal antibody (anti-Claudin 18.2)	NICEUK	Not recommended	Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaWith fluoropyrimidine and platinum chemotherapy for untreated claudin-18.2-positive HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
2025-03-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Verfahren abgeschlossen	Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Hochrisiko-Erstrezidiv, Ph-, CD19+, ≥1 Monat und <1 Jahr)Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Hochrisiko-Erstrezidiv, Ph-, CD19+, ≥1 Monat und <1 Jahr
2025-03-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Verfahren abgeschlossen	Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert)Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, Ph-, CD19+, neu diagnostiziert
2025-03-01	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	G-BAGermany	Verfahren abgeschlossen	Blinatumomab (Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, rezidiviert / refraktär, ≥ 1 Monat bis < 1 Jahr, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation)Neues Anwendungsgebiet: Akute lymphatische B-Zell-Leukämie, rezidiviert / refraktär, ≥ 1 Monat bis < 1 Jahr, nach ≥ 2 Vortherapien oder nach allogener Stammzelltransplantation
2025-03-01	Daratumumab Darzalex · Monoclonal antibody (anti-CD38)	G-BAGermany	Verfahren abgeschlossen	Daratumumab (Neubewertung nach Fristablauf: systemische Leichtketten-Amyloidose, Erstlinie, Kombination mit Cyclophosphamid, Bortezomib und Dexamethason)Neubewertung nach Fristablauf: systemische Leichtketten-Amyloidose, Erstlinie, Kombination mit Cyclophosphamid, Bortezomib und Dexamethason
2025-03-01	Fedratinib Inrebic · Small-molecule JAK2/FLT3 inhibitor	G-BAGermany	Verfahren abgeschlossen	Fedratinib (Neubewertung nach Fristablauf: Myelofibrose)Neubewertung nach Fristablauf: Myelofibrose
2025-03-01	Setmelanotide Imcivree · Subcutaneous melanocortin-4 receptor agonist	G-BAGermany	Verfahren abgeschlossen	Setmelanotid (Neues Anwendungsgebiet: Adipositas und Kontrolle von Hunger, POMC-, PCSK1-, LEPR-Mangel oder Bardet-Biedl-Syndrom, ≥ 2 bis < 6 Jahre)Neues Anwendungsgebiet: Adipositas und Kontrolle von Hunger, POMC-, PCSK1-, LEPR-Mangel oder Bardet-Biedl-Syndrom, ≥ 2 bis < 6 Jahre
2025-02-15	Dostarlimab Jemperli · Monoclonal antibody (anti-PD-1)	G-BAGermany	Verfahren abgeschlossen	Dostarlimab (Neues Anwendungsgebiet: primär fortgeschrittenes oder rezidiviertes Endometriumkarzinom mit pMMR, Kombination mit Carboplatin und Paclitaxel)Neues Anwendungsgebiet: primär fortgeschrittenes oder rezidiviertes Endometriumkarzinom mit pMMR, Kombination mit Carboplatin und Paclitaxel
2025-02-15	Isatuximab Sarclisa · Monoclonal antibody (anti-CD38)	G-BAGermany	Verfahren abgeschlossen	Isatuximab (Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason)Neues Anwendungsgebiet: Multiples Myelom, Erstlinie, Stammzelltransplantation ungeeignet, Kombination mit Bortezomib, Lenalidomid und Dexamethason
2025-02-15	Lazertinib Lazcluze · Small-molecule kinase inhibitor (EGFR)	G-BAGermany	Verfahren abgeschlossen	Lazertinib (Nicht-kleinzelliges Lungenkarzinom, EGFR-Exon19-Deletionen oder Exon 21-Substitutionsmutationen (L858R), Kombination mit Amivantamab)Nicht-kleinzelliges Lungenkarzinom, EGFR-Exon19-Deletionen oder Exon 21-Substitutionsmutationen (L858R), Kombination mit Amivantamab
2025-02-15	Nintedanib Ofev · Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)	G-BAGermany	Verfahren abgeschlossen	Nintedanib (Neues Anwendungsgebiet: interstitielle Lungenerkrankung mit systemischer Sklerose, 6 bis < 18 Jahre)Neues Anwendungsgebiet: interstitielle Lungenerkrankung mit systemischer Sklerose, 6 bis < 18 Jahre
2025-02-15	Nintedanib Ofev · Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)	G-BAGermany	Verfahren abgeschlossen	Nintedanib (Neues Anwendungsgebiet: klinisch signifikante progredient fibrosierende interstitielle Lungenerkrankungen, 6 bis < 18 Jahre)Neues Anwendungsgebiet: klinisch signifikante progredient fibrosierende interstitielle Lungenerkrankungen, 6 bis < 18 Jahre
2025-02-15	Pirtobrutinib Jaypirca · Small-molecule non-covalent (reversible) BTK inhibitor	G-BAGermany	Verfahren abgeschlossen	Pirtobrutinib (Mantelzell-Lymphom, vorbehandelte Patienten)Mantelzell-Lymphom, vorbehandelte Patienten
2025-02-05	Elacestrant Orserdu · Oral SERD	NICEUK	Recommended (optimised)	Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentER-positive HER2-negative advanced breast cancer with an activating ESR1 mutation after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor
2025-02-01	Amivantamab Rybrevant · Bispecific antibody (EGFR×MET)	G-BAGermany	Verfahren abgeschlossen	Amivantamab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), Kombination mit Lazertinib)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), Kombination mit Lazertinib
2025-02-01	Amivantamab Rybrevant · Bispecific antibody (EGFR×MET)	G-BAGermany	Verfahren abgeschlossen	Amivantamab (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), vorbehandelt, Kombination mit Carboplatin und Pemetrexed)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR Exon-19-Deletionen oder Exon-21-Substitutionsmutationen (L858R), vorbehandelt, Kombination mit Carboplatin und Pemetrexed
2025-02-01	Amivantamab Rybrevant · Bispecific antibody (EGFR×MET)	G-BAGermany	Verfahren abgeschlossen	Amivantamab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR Exon-20-Insertionsmutation, Erstlinie, Kombination mit Carboplatin und Pemetrexed)Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR Exon-20-Insertionsmutation, Erstlinie, Kombination mit Carboplatin und Pemetrexed
2025-01-22	Sodium thiosulfate (otoprotectant) Pedmark · Small-molecule chemoprotectant	NICEUK	Recommended	Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursPreventing hearing loss from cisplatin chemotherapy in people aged 1 month to 17 years with localised, non-metastatic solid tumours
2025-01-15	Osimertinib Tagrisso · Small-molecule kinase inhibitor (EGFR)	G-BAGermany	Verfahren abgeschlossen	Osimertinib (Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR-Mutationen, nach platinbasierter Radiochemotherapie)Neues Anwendungsgebiet: Nicht-kleinzelliges Lungenkarzinom, EGFR-Mutationen, nach platinbasierter Radiochemotherapie
2025-01-09	Tebentafusp Kimmtrak · ImmTAC (TCR×CD3 bispecific)	NICEUK	Recommended	Tebentafusp for treating advanced uveal melanomaHLA-A*02:01-positive unresectable or metastatic uveal melanoma
2025-01-01	Erdafitinib Balversa · Small-molecule kinase inhibitor (pan-FGFR)	G-BAGermany	Verfahren abgeschlossen	Erdafitinib (Urothelkarzinom, FGFR3 Veränderungen, vorbehandelt mit PD-(L)1-Inhibitor)Urothelkarzinom, FGFR3 Veränderungen, vorbehandelt mit PD-(L)1-Inhibitor
2025	Adagrasib Krazati · Small-molecule inhibitor (KRAS G12C)	NICEUK	Terminated	Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)Previously treated KRAS G12C mutation-positive advanced NSCLC
2025	Idecabtagene vicleucel Abecma · CAR-T (BCMA)	NICEUK	Terminated	Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)Relapsed or refractory multiple myeloma after 2 to 4 treatments
2025	NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) Onivyde regimen · Cytotoxic regimen	NICEUK	Terminated	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)Liposomal irinotecan with oxaliplatin, fluorouracil and folinic acid for untreated metastatic pancreatic cancer
2025	Tislelizumab Tevimbra · Monoclonal antibody (anti-PD-1)	NICEUK	Terminated	Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)Unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy
2024-12-11	Elranatamab Elrexfio · Bispecific T-cell engager (BCMA×CD3)	NICEUK	Cancer Drugs Fund	Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsRelapsed and refractory multiple myeloma after 3 or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) that progressed on the last treatment
2024-11-13	Teclistamab Tecvayli · Bispecific T-cell engager (BCMA×CD3)	NICEUK	Recommended	Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsRelapsed and refractory multiple myeloma after 3 or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) that progressed on the last treatment
2024-11-06	Avapritinib Ayvakit · Small-molecule kinase inhibitor (PDGFRA D842V / KIT)	NICEUK	Recommended	Avapritinib for treating advanced systemic mastocytosisAdvanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
2024-10-23	Quizartinib Vanflyta · Small-molecule kinase inhibitor (FLT3-ITD, type II)	NICEUK	Recommended	Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaNewly diagnosed FLT3-ITD-positive AML with standard induction and consolidation chemotherapy, then alone as maintenance
2024-10-16	Belzutifan Welireg · Small-molecule HIF-2α inhibitor	NICEUK	Cancer Drugs Fund	Belzutifan for treating tumours associated with von Hippel-Lindau diseaseVon Hippel-Lindau disease needing treatment for associated renal cell carcinomas, CNS haemangioblastomas or pancreatic neuroendocrine tumours when localised procedures are unsuitable
2024-09-11	Futibatinib Lytgobi · Small-molecule irreversible kinase inhibitor (FGFR1-4)	NICEUK	Recommended	Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementLocally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement after at least 1 line of systemic treatment
2024-08-14	Relugolix Orgovyx · Oral GnRH antagonist	NICEUK	Recommended	Relugolix for treating hormone-sensitive prostate cancerAdvanced hormone-sensitive prostate cancer, and alongside or before radiotherapy for high-risk localised or locally advanced disease
2024-05-08	Selinexor Xpovio · Small-molecule XPO1 (nuclear export) inhibitor	NICEUK	Recommended	Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsWith dexamethasone for penta-refractory multiple myeloma after 4 or more treatments that progressed on the last treatment
2024-03-20	Momelotinib Ojjaara / Omjjara · Small-molecule JAK1/JAK2/ACVR1 inhibitor	NICEUK	Recommended (optimised)	Momelotinib for treating myelofibrosis-related splenomegaly or symptomsIntermediate-2 or high-risk myelofibrosis with moderate to severe anaemia, in people who have not had a JAK inhibitor or have had ruxolitinib
2024-03-06	Epcoritamab Epkinly · Bispecific T-cell engager (CD20×CD3)	NICEUK	Cancer Drugs Fund	Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsRelapsed or refractory DLBCL after 2 or more systemic treatments
2024-02-21	Talazoparib Talzenna · Small-molecule PARP inhibitor	NICEUK	Recommended	Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsHER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 mutations after an anthracycline or taxane (and endocrine therapy if HR-positive)
2024-02-07	Belumosudil Rezurock · Oral ROCK2 inhibitor	NICEUK	Recommended	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overChronic graft-versus-host disease after 2 or more systemic treatments in people aged 12 and over
2024-02-07	Relatlimab + nivolumab Opdualag · Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)	NICEUK	Recommended (optimised)	Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overUntreated advanced (unresectable or metastatic) melanoma in people 12 years and over, stopped after 2 years
2024-01-31	Ivosidenib Tibsovo · Small-molecule IDH1 inhibitor	NICEUK	Recommended	Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsLocally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
2024-01-31	Loncastuximab tesirine Zynlonta · ADC	NICEUK	Recommended (optimised)	Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsRelapsed or refractory DLBCL or high-grade B-cell lymphoma after 2 or more systemic treatments, only after polatuzumab vedotin or where it is contraindicated or not tolerated
2023-11-22	Zanubrutinib Brukinsa · Small-molecule covalent BTK inhibitor (second generation)	NICEUK	Recommended	Zanubrutinib for treating chronic lymphocytic leukaemiaUntreated CLL (with 17p/TP53 or unsuitable for FCR/BR) and CLL after 1 prior therapy
2023-11-15	Lutetium-177 vipivotide tetraxetan Pluvicto · Radioligand therapy (beta)	NICEUK	Not recommended	Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsPSMA-positive hormone-relapsed metastatic prostate cancer after taxane chemotherapy and an anti-androgen, or when taxanes are medically unsuitable (VISION)
2023-10-17	Glofitamab Columvi · Bispecific T-cell engager (CD20×CD3, 2:1)	NICEUK	Recommended	Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsRelapsed or refractory DLBCL after 2 or more systemic treatments
2023-10-04	Tremelimumab Imjudo · Monoclonal antibody (anti-CTLA-4)	NICEUK	TA page does not name this product	Bimekizumab for treating active psoriatic arthritisCurated status recommended; the cited TA number may be wrong or renumbered
2023-05-31	Mosunetuzumab Lunsumio · Bispecific T-cell engager (CD20×CD3)	NICEUK	Not recommended	Mosunetuzumab for treating relapsed or refractory follicular lymphomaRelapsed or refractory follicular lymphoma after 2 or more systemic treatments
2023-05-03	Tafasitamab Monjuvi · Monoclonal antibody (anti-CD19, Fc-enhanced)	NICEUK	Not recommended	Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaWith lenalidomide for relapsed or refractory DLBCL in people who cannot have an autologous stem cell transplant
2023	Capmatinib Tabrecta · Small-molecule MET tyrosine kinase inhibitor	NICEUK	Terminated	Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)Advanced NSCLC with MET exon 14 skipping
2023	Ciltacabtagene autoleucel Carvykti · CAR-T (BCMA)	NICEUK	Terminated	Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)Relapsed or refractory multiple myeloma
2023	Decitabine + cedazuridine (oral) Inqovi · Oral hypomethylating agent	NICEUK	Terminated	Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)Untreated AML when intensive chemotherapy is unsuitable
2022-08-17	Sacituzumab govitecan Trodelvy · ADC	NICEUK	Recommended	Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesUnresectable triple-negative breast cancer after 2 or more systemic treatments
2022-08-10	Alpelisib Piqray · Small-molecule PI3Kα inhibitor	NICEUK	Recommended	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerWith fulvestrant for PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor
2022-08-03	Asciminib Scemblix · Small-molecule allosteric ABL1 inhibitor (STAMP)	NICEUK	Recommended	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsChronic phase CML after 2 or more TKIs
2022-08-03	Pralsetinib Gavreto · Small-molecule kinase inhibitor (RET)	NICEUK	Not recommended	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerRET fusion-positive advanced NSCLC in people who have not had a RET inhibitor
2022-06-29	Cemiplimab Libtayo · Monoclonal antibody (anti-PD-1)	NICEUK	Recommended (optimised)	Cemiplimab for treating advanced cutaneous squamous cell carcinomaMetastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, stopped at 24 months
2022-05-18	Capmatinib & tepotinib Tabrecta / Tepmetko · Small-molecule kinase inhibitors (MET)	NICEUK	Recommended	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTepotinib for MET exon 14 skipping advanced NSCLC
2022-05-18	Tepotinib Tepmetko · Small-molecule MET tyrosine kinase inhibitor	NICEUK	Recommended	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsAdvanced NSCLC with MET exon 14 skipping alterations
2022-05-11	Avelumab Bavencio · Monoclonal antibody (anti-PD-L1)	NICEUK	Recommended	Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyMaintenance for urothelial cancer after platinum chemotherapy (JAVELIN Bladder 100)
2022-04-27	Tucatinib Tukysa · Small-molecule kinase inhibitor (HER2)	NICEUK	Recommended	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesWith trastuzumab and capecitabine for HER2-positive breast cancer after 2 or more anti-HER2 treatments
2022-03-30	Sotorasib Lumakras · Small-molecule inhibitor (KRAS G12C)	NICEUK	Cancer Drugs Fund	Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerKRAS G12C-mutated advanced NSCLC after 1 or more systemic therapies
2022	Luspatercept Reblozyl · Erythroid maturation agent (activin receptor IIB ligand trap, Fc fusion)	NICEUK	Terminated	Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)Anaemia caused by myelodysplastic syndromes
2022	Tagraxofusp Elzonris · Recombinant cytotoxin (IL-3 fused to diphtheria toxin)	NICEUK	Terminated	Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)Blastic plasmacytoid dendritic cell neoplasm
2021-12-16	Fedratinib Inrebic · Small-molecule JAK2/FLT3 inhibitor	NICEUK	Superseded by newer guidance	Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisMyelofibrosis-related splenomegaly or symptoms after ruxolitinib
2021-12-15	Mogamulizumab Poteligeo · Defucosylated anti-CCR4 monoclonal antibody	NICEUK	Recommended (optimised)	Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeSézary syndrome after at least 1 systemic treatment; mycosis fungoides stage 2B or above after at least 2 systemic treatments
2021-11-03	Selpercatinib Retevmo · Small-molecule kinase inhibitor (RET)	NICEUK	Superseded by newer guidance	Selpercatinib for treating advanced thyroid cancer with RET alterationsRET fusion-positive advanced NSCLC after platinum chemotherapy
2021-10-28	Apalutamide Erleada · Small-molecule AR antagonist	NICEUK	Recommended	Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerWith androgen deprivation therapy for high-risk hormone-relapsed non-metastatic prostate cancer, high risk being a PSA that has doubled in 10 months or less
2021-08-25	Pemigatinib Pemazyre · Small-molecule kinase inhibitor (FGFR1-3)	NICEUK	Recommended	Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangementFGFR2 fusion or rearrangement-positive cholangiocarcinoma after 1 or more systemic therapies
2021-05-26	Trastuzumab deruxtecan Enhertu · ADC	NICEUK	Cancer Drugs Fund	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesHER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 treatments
2021-04-21	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	NICEUK	Recommended	Acalabrutinib for treating chronic lymphocytic leukaemiaUntreated CLL (with 17p/TP53 or unsuitable for FCR/BR) and CLL after 1 prior therapy
2021-02-24	Brexucabtagene autoleucel Tecartus · Autologous CD19 CAR-T (CD28 costimulatory domain)	NICEUK	Cancer Drugs Fund	Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaRelapsed or refractory mantle cell lymphoma after a BTK inhibitor
2021-01-27	Brigatinib Alunbrig · Small-molecule ALK/EGFR TKI (second generation)	NICEUK	Recommended	Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorUntreated ALK-positive advanced NSCLC
2020-12-09	Venetoclax Venclexta · Small-molecule BCL-2 inhibitor	NICEUK	Superseded by newer guidance	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaWith obinutuzumab for untreated CLL
2020-11-25	Darolutamide Nubeqa · Small-molecule AR antagonist	NICEUK	Recommended	Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerHigh-risk non-metastatic hormone-relapsed prostate cancer
2020-11-18	Isatuximab Sarclisa / Sarclisa Escena (SC) · Monoclonal antibody (anti-CD38)	NICEUK	Superseded by newer guidance	Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaWith pomalidomide and dexamethasone for myeloma after 3 or more treatments
2020-10-14	Osimertinib Tagrisso · Small-molecule kinase inhibitor (EGFR)	NICEUK	Cancer Drugs Fund	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerUntreated EGFR mutation-positive NSCLC (FLAURA)
2020-09-23	Polatuzumab vedotin Polivy · ADC	NICEUK	Recommended	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaWith rituximab and bendamustine for relapsed or refractory DLBCL in adults who cannot have a haematopoietic stem cell transplant
2020-08-12	Entrectinib Rozlytrek · Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)	NICEUK	Cancer Drugs Fund	Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerNTRK fusion-positive solid tumours (histology-independent)
2020-08-12	Gilteritinib Xospata · Small-molecule kinase inhibitor (FLT3, type I)	NICEUK	Recommended	Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaRelapsed or refractory FLT3 mutation-positive AML
2020-08-05	Treosulfan Grafapex · Alkylating conditioning agent (busulfan analogue)	NICEUK	Recommended	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantWith fludarabine as conditioning before allogeneic stem cell transplant for malignant disease, where a reduced-intensity regimen would be suitable
2020-05-27	Larotrectinib Vitrakvi · Small-molecule pan-TRK inhibitor (first generation)	NICEUK	Cancer Drugs Fund	Larotrectinib for treating NTRK fusion-positive solid tumoursNTRK fusion-positive solid tumours (histology-independent)
2020-05-13	Lorlatinib Lorbrena · Small-molecule kinase inhibitor (ALK/ROS1)	NICEUK	Cancer Drugs Fund	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerALK-positive NSCLC after alectinib, ceritinib or crizotinib then another TKI
2019-11-20	Neratinib Nerlynx · Small-molecule irreversible pan-HER kinase inhibitor	NICEUK	Recommended	Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabExtended adjuvant treatment of HR-positive, HER2-positive early breast cancer completed less than 1 year after trastuzumab
2019-11-13	Rucaparib Rubraca · Small-molecule PARP inhibitor	NICEUK	Superseded by newer guidance	Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerMaintenance for relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
2019-08-14	Dacomitinib Vizimpro · Small-molecule pan-ErbB TKI (second generation, irreversible)	NICEUK	Recommended	Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerUntreated EGFR mutation-positive NSCLC
2019-05-01	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	NICEUK	Superseded by newer guidance	Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiationUnresectable stage III NSCLC after chemoradiation (PACIFIC)
2019-04-10	Daratumumab Darzalex / Darzalex Faspro (SC) · Monoclonal antibody (anti-CD38)	NICEUK	Superseded by newer guidance	Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaWith bortezomib and dexamethasone for myeloma after 1 prior therapy (CASTOR)
2019-02-27	Abemaciclib Verzenio · Small-molecule CDK4/6 inhibitor	NICEUK	Recommended	Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerWith an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer
2019-02-27	Binimetinib Mektovi · Small-molecule kinase inhibitor (MEK1/2)	NICEUK	Recommended	Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaWith encorafenib for BRAF V600 mutation-positive melanoma
2019-02-27	Encorafenib Braftovi · Small-molecule kinase inhibitor (BRAF)	NICEUK	Recommended	Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanomaWith binimetinib for BRAF V600 mutation-positive melanoma
2019-01-23	Axicabtagene ciloleucel Yescarta · CAR-T (CD19)	NICEUK	Superseded by newer guidance	Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesRelapsed or refractory DLBCL or PMBCL after 2 or more systemic therapies
2019-01-09	Regorafenib Stivarga · Small-molecule multi-kinase inhibitor	NICEUK	Recommended	Regorafenib for previously treated advanced hepatocellular carcinomaAdvanced HCC after sorafenib
2018-12-21	Tisagenlecleucel Kymriah · CAR-T (CD19)	NICEUK	Superseded by newer guidance	Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 yearsRelapsed or refractory B-cell ALL in people up to 25 years
2018-12-19	CPX-351 (liposomal daunorubicin-cytarabine) Vyxeos · Liposomal cytotoxic formulation	NICEUK	Recommended	Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemiaUntreated therapy-related AML or AML with myelodysplasia-related changes
2018-12-19	Lenvatinib Lenvima · Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)	NICEUK	Recommended	Lenvatinib for untreated advanced hepatocellular carcinomaUntreated advanced HCC
2018-12-12	Vandetanib Caprelsa · Small-molecule kinase inhibitor (RET, VEGFR, EGFR)	NICEUK	Not recommended	Vandetanib for treating medullary thyroid cancerAggressive and symptomatic unresectable, locally advanced or metastatic medullary thyroid cancer
2018-11-14	Gemtuzumab ozogamicin Mylotarg · ADC	NICEUK	Recommended	Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaUntreated de novo CD33-positive AML with standard induction chemotherapy
2018-09-19	Inotuzumab ozogamicin Besponsa · ADC	NICEUK	Recommended	Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaRelapsed or refractory CD22-positive B-cell precursor ALL
2018-08-29	Lutetium-177 dotatate Lutathera · Radioligand therapy (beta)	NICEUK	Recommended	Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursUnresectable or metastatic, progressive, well-differentiated somatostatin receptor-positive GEP-NETs
2018-08-22	Dinutuximab (ch14.18) / dinutuximab beta Unituxin / Qarziba (EU) · Monoclonal antibody (anti-GD2, chimeric)	NICEUK	Recommended	Dinutuximab beta for treating neuroblastomaHigh-risk neuroblastoma after induction, high-dose chemotherapy and stem cell transplant, or relapsed/refractory
2018-08-08	Alectinib Alecensa · Small-molecule kinase inhibitor (ALK)	NICEUK	Recommended	Alectinib for untreated ALK-positive advanced non-small-cell lung cancerUntreated ALK-positive advanced NSCLC
2018-07-18	Pembrolizumab Keytruda / Keytruda Qlex (SC) · Monoclonal antibody (anti-PD-1)	NICEUK	Recommended (optimised)	Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerUntreated PD-L1 ≥50% metastatic NSCLC (2-year stopping rule)
2018-07-04	Niraparib Zejula · Small-molecule PARP inhibitor	NICEUK	Superseded by newer guidance	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerMaintenance for relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
2018-06-13	Arsenic trioxide Trisenox · Inorganic arsenical (differentiation agent)	NICEUK	Recommended	Arsenic trioxide for treating acute promyelocytic leukaemiaAcute promyelocytic leukaemia (untreated low-to-intermediate risk with ATRA, and relapsed)
2018-06-13	Midostaurin Rydapt · Small-molecule multikinase inhibitor (FLT3)	NICEUK	Recommended	Midostaurin for untreated acute myeloid leukaemiaUntreated FLT3 mutation-positive AML with standard chemotherapy
2018-05-16	Atezolizumab Tecentriq / Tecentriq Hybreza (SC) · Monoclonal antibody (anti-PD-L1)	NICEUK	Recommended	Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyNSCLC after chemotherapy
2018-03-21	Tivozanib Fotivda · Small-molecule kinase inhibitor (VEGFR)	NICEUK	Recommended	Tivozanib for treating advanced renal cell carcinomaFirst-line advanced RCC
2018-03-07	Pertuzumab Perjeta; Phesgo (with trastuzumab, subcutaneous) · Monoclonal antibody (anti-HER2, dimerisation domain)	NICEUK	Recommended	Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancerWith trastuzumab and docetaxel for HER2-positive metastatic breast cancer
2018-02-07	Ixazomib Ninlaro · Oral proteasome inhibitor (boronate)	NICEUK	Superseded by newer guidance	Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaWith lenalidomide and dexamethasone for myeloma after 2 or 3 lines
2018-01-24	Ceritinib Zykadia · Small-molecule ALK TKI (second generation)	NICEUK	Recommended	Ceritinib for untreated ALK-positive non-small-cell lung cancerUntreated ALK-positive advanced NSCLC
2017-12-20	Palbociclib Ibrance · Small-molecule CDK4/6 inhibitor	NICEUK	Recommended	Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerWith an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer
2017-12-20	Ribociclib Kisqali · Small-molecule CDK4/6 inhibitor	NICEUK	Recommended	Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerWith an aromatase inhibitor for untreated HR-positive, HER2-negative advanced breast cancer
2017-11-22	Vismodegib Erivedge · Small-molecule smoothened (hedgehog) inhibitor	NICEUK	Not recommended	Vismodegib for treating basal cell carcinomaSymptomatic metastatic or locally advanced basal cell carcinoma unsuitable for surgery or radiotherapy
2017-11-01	Nivolumab Opdivo / Opdivo Qvantig (SC) · Monoclonal antibody (anti-PD-1)	NICEUK	Superseded by newer guidance	Nivolumab for previously treated non-squamous non-small-cell lung cancerPreviously treated non-squamous NSCLC
2017-09-06	Paclitaxel / nab-paclitaxel Taxol / Abraxane · Cytotoxic chemotherapy (taxane)	NICEUK	Recommended	Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancerNab-paclitaxel with gemcitabine for untreated metastatic pancreatic cancer
2017-09-06	Sorafenib Nexavar · Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)	NICEUK	Recommended	Sorafenib for treating advanced hepatocellular carcinomaAdvanced HCC (Child-Pugh A)
2017-08-09	Cabozantinib Cabometyx · Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)	NICEUK	Recommended	Cabozantinib for previously treated advanced renal cell carcinomaAdvanced RCC after VEGF-targeted therapy
2017-07-19	Carfilzomib Kyprolis · Proteasome inhibitor (irreversible)	NICEUK	Recommended	Carfilzomib for previously treated multiple myelomaWith dexamethasone for myeloma after 1 prior therapy
2017-07-19updated 2017-11-20	Trastuzumab emtansine Kadcyla · ADC	NICEUK	Recommended	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneHER2-positive metastatic breast cancer after trastuzumab and a taxane
2017-06-28	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	NICEUK	Recommended	Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemiaPhiladelphia-negative relapsed or refractory B-cell precursor ALL
2017-06-28	Brentuximab vedotin Adcetris · ADC	NICEUK	Superseded by newer guidance	Brentuximab vedotin for treating CD30-positive Hodgkin lymphomaCD30-positive Hodgkin lymphoma after autologous transplant or 2 prior therapies
2017-06-28	Ponatinib Iclusig · Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)	NICEUK	Recommended	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemiaCML or Ph-positive ALL resistant to dasatinib or nilotinib, or with T315I
2017-03-29updated 2017-09-25	Cetuximab Erbitux · Monoclonal antibody (anti-EGFR)	NICEUK	Recommended	Cetuximab and panitumumab for previously untreated metastatic colorectal cancerWith chemotherapy for untreated RAS wild-type metastatic colorectal cancer
2017-03-29updated 2017-09-25	Panitumumab Vectibix · Monoclonal antibody (anti-EGFR)	NICEUK	Recommended	Cetuximab and panitumumab for previously untreated metastatic colorectal cancerWith chemotherapy for untreated RAS wild-type metastatic colorectal cancer
2017-02-22	Everolimus Afinitor · Small-molecule mTOR inhibitor	NICEUK	Recommended	Everolimus for advanced renal cell carcinoma after previous treatmentAdvanced renal cell carcinoma after previous treatment
2017-01-25	Ibrutinib Imbruvica · Small-molecule covalent BTK inhibitor (first generation)	NICEUK	Recommended	Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationCLL after 1 prior therapy, or untreated CLL with 17p deletion or TP53 mutation
2017-01-11	Pomalidomide Pomalyst / Imnovid · Oral cereblon E3 ligase modulator (IMiD)	NICEUK	Recommended	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibMultiple myeloma after 3 or more treatments including lenalidomide and bortezomib
2017	Elotuzumab Empliciti · Anti-SLAMF7 monoclonal antibody	NICEUK	Terminated	Elotuzumab for previously treated multiple myeloma (terminated appraisal)Previously treated multiple myeloma
2016-12-21	Dasatinib Sprycel · Small-molecule kinase inhibitor (BCR::ABL1, SRC)	NICEUK	Recommended	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaCML resistant or intolerant to imatinib
2016-12-21	Eribulin Halaven · Synthetic halichondrin B analogue (microtubule dynamics inhibitor)	NICEUK	Recommended	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensLocally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
2016-10-26	Cobimetinib Cotellic · Small-molecule kinase inhibitor (MEK1/2)	NICEUK	Recommended	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaWith vemurafenib for BRAF V600 mutation-positive melanoma
2016-09-28	Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) Oncaspar / Asparlas / Rylaze / Erwinaze · Enzyme therapy	NICEUK	Recommended	Pegaspargase for treating acute lymphoblastic leukaemiaAcute lymphoblastic leukaemia in children, young people and adults
2016-09-28	Crizotinib Xalkori · Small-molecule ALK/ROS1/MET TKI (first generation)	NICEUK	Recommended	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerUntreated ALK-positive advanced NSCLC
2016-09-28	Radium-223 dichloride Xofigo · Targeted alpha therapy (bone-seeking)	NICEUK	Recommended	Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesHormone-relapsed prostate cancer with bone metastases after docetaxel (or not suitable for it)
2016-09-28	Talimogene laherparepvec Imlygic · Oncolytic virus (HSV-1)	NICEUK	Recommended	Talimogene laherparepvec for treating unresectable metastatic melanomaUnresectable regionally or distantly metastatic melanoma (stage IIIB-IVM1a) when systemically administered immunotherapy is not suitable
2016-08-24	Bosutinib Bosulif · Small-molecule BCR-ABL1/SRC TKI	NICEUK	Recommended	Bosutinib for previously treated chronic myeloid leukaemiaCML after prior TKI when imatinib, nilotinib and dasatinib are not appropriate
2016-08-24	Degarelix Firmagon · GnRH antagonist depot	NICEUK	Recommended	Degarelix for treating advanced hormone-dependent prostate cancerAdvanced hormone-dependent prostate cancer with spinal metastases
2016-08-24	Trifluridine/tipiracil Lonsurf · Cytotoxic chemotherapy (oral nucleoside)	NICEUK	Recommended	Trifluridine–tipiracil for previously treated metastatic colorectal cancerMetastatic colorectal cancer after standard therapies
2016-06-22	Dabrafenib + trametinib Tafinlar + Mekinist · Small-molecule kinase inhibitors (BRAF + MEK)	NICEUK	Recommended	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaUnresectable or metastatic BRAF V600-mutated melanoma
2016-05-25updated 2016-08-24	Cabazitaxel Jevtana · Cytotoxic chemotherapy (taxane)	NICEUK	Recommended	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelMetastatic hormone-relapsed prostate cancer after docetaxel
2016-03-23	Ruxolitinib Jakafi / Jakavi · Small-molecule JAK1/JAK2 inhibitor	NICEUK	Recommended	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosisDisease-related splenomegaly or symptoms in myelofibrosis (intermediate-2 or high risk)
2016-01-27	Olaparib Lynparza · Small-molecule PARP inhibitor	NICEUK	Superseded by newer guidance	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapyMaintenance for relapsed platinum-sensitive BRCA-mutated ovarian cancer
2016-01-27	Ramucirumab Cyramza · Monoclonal antibody (anti-VEGFR2)	NICEUK	Not recommended	Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyAdvanced gastric or gastro-oesophageal junction cancer after chemotherapy
2015-10-28	Idelalisib Zydelig · Small-molecule PI3Kδ inhibitor	NICEUK	Recommended	Idelalisib for treating chronic lymphocytic leukaemiaWith rituximab for CLL after 1 prior therapy or untreated with 17p/TP53
2015-06-02	Obinutuzumab Gazyva · Monoclonal antibody (anti-CD20, glycoengineered type II)	NICEUK	Recommended	Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemiaWith chlorambucil for untreated CLL unsuitable for fludarabine-based therapy
2015-02-25	Axitinib Inlyta · Small-molecule kinase inhibitor (VEGFR)	NICEUK	Recommended	Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentAdvanced RCC after failure of prior systemic treatment
2015-02-23	Sipuleucel-T Provenge · Autologous cellular immunotherapy (antigen-presenting cell vaccine)	NICEUK	Not recommended	Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancerAsymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
2014-07-23	Enzalutamide Xtandi · Small-molecule AR antagonist	NICEUK	Recommended	Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimenMetastatic hormone-relapsed prostate cancer after docetaxel
2014-07-23	Ipilimumab Yervoy · Monoclonal antibody (anti-CTLA-4)	NICEUK	Recommended	Ipilimumab for previously untreated advanced (unresectable or metastatic) melanomaPreviously untreated advanced melanoma
2014-04-23	Afatinib Gilotrif / Giotrif · Small-molecule pan-ErbB TKI (second generation, irreversible)	NICEUK	Recommended	Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancerUntreated EGFR mutation-positive NSCLC
2012-12-12updated 2015-01-01	Vemurafenib Zelboraf · Small-molecule kinase inhibitor (BRAF V600)	NICEUK	Recommended	Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanomaBRAF V600 mutation-positive unresectable or metastatic melanoma
2012-06-27updated 2016-07-27	Abiraterone acetate Zytiga (generic) · Small-molecule CYP17A1 inhibitor	NICEUK	Recommended	Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenMetastatic hormone-relapsed prostate cancer after docetaxel
2012-06-27	Erlotinib Tarceva · Small-molecule EGFR TKI (first generation, reversible)	NICEUK	Recommended	Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancerUntreated EGFR mutation-positive NSCLC
2012-06-27	Lapatinib Tykerb · Small-molecule reversible HER2/EGFR kinase inhibitor	NICEUK	Not recommended	Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2With an aromatase inhibitor for HER2-positive, HR-positive metastatic breast cancer
2012-04-25	Nilotinib Tasigna · Small-molecule BCR-ABL1 TKI (second generation)	NICEUK	Superseded by newer guidance	Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemiaUntreated chronic phase CML (dasatinib, nilotinib and standard-dose imatinib)
2011-12-14	Fulvestrant Faslodex · Injectable SERD	NICEUK	Not recommended	Fulvestrant for the treatment of locally advanced or metastatic breast cancerLocally advanced or metastatic breast cancer as monotherapy
2011-10-26	Mifamurtide Mepact · Liposomal muramyl tripeptide (macrophage activator)	NICEUK	Recommended	Mifamurtide for the treatment of osteosarcomaHigh-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection (age 2-30)
2011-07-27	Thalidomide Thalomid · Oral cereblon modulator (first IMiD)	NICEUK	Recommended	Bortezomib and thalidomide for the first‑line treatment of multiple myelomaUntreated multiple myeloma with an alkylating agent and a corticosteroid (transplant-ineligible)
2011-03-23	Azacitidine Vidaza / Onureg (oral) · Small-molecule hypomethylating agent (cytotoxic)	NICEUK	Recommended	Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaIntermediate-2 or high-risk MDS, CMML, and AML with 20-30% blasts not eligible for transplant
2011-02-23	Bendamustine Treanda / Bendeka / Belrapzo · Alkylating agent (nitrogen mustard-purine hybrid)	NICEUK	Recommended	Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaFirst-line CLL (Binet B/C) when fludarabine combination is not appropriate
2011-02-23updated 2013-08-01	Pazopanib Votrient · Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)	NICEUK	Recommended	Pazopanib for the first-line treatment of advanced renal cell carcinomaFirst-line advanced RCC
2010-07-28	Gefitinib Iressa · Small-molecule EGFR TKI (first generation, reversible)	NICEUK	Recommended	Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancerUntreated EGFR mutation-positive NSCLC
2010-02-24updated 2021-02-08	Trabectedin Yondelis · Cytotoxic (DNA minor-groove binder)	NICEUK	Recommended	Trabectedin for the treatment of advanced soft tissue sarcomaAdvanced soft tissue sarcoma after anthracyclines and ifosfamide
2009-11-25	Topotecan Hycamtin · Cytotoxic (topoisomerase-I inhibitor)	NICEUK	Recommended	Topotecan for the treatment of relapsed small-cell lung cancerRelapsed small-cell lung cancer
2009-09-23	Pemetrexed Alimta (and generics) · Cytotoxic (antifolate)	NICEUK	Recommended	Pemetrexed for the first-line treatment of non-small-cell lung cancerFirst-line treatment of non-squamous NSCLC with cisplatin
2009-08-26	Temsirolimus Torisel · Intravenous mTOR inhibitor (rapamycin analogue)	NICEUK	Not recommended	Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinomaFirst-line poor-prognosis advanced RCC
2009-06-18updated 2019-06-26	Lenalidomide Revlimid · Immunomodulatory drug (cereblon E3 ligase modulator)	NICEUK	Recommended	Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapiesMultiple myeloma after 2 or more prior therapies
2009-03-25	Sunitinib Sutent · Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)	NICEUK	Recommended	Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinomaFirst-line advanced or metastatic RCC
2007-10-23	Bortezomib Velcade · Proteasome inhibitor	NICEUK	Recommended	Bortezomib monotherapy for relapsed multiple myelomaMultiple myeloma at first relapse
2006-11-22	Letrozole (and other aromatase inhibitors) Femara; anastrozole (Arimidex); exemestane (Aromasin) · Small-molecule aromatase inhibitor	NICEUK	TA page does not name this product	Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancerCurated status recommended; the cited TA number may be wrong or renumbered
2005-08-24	Irinotecan (and liposomal irinotecan) Camptosar / Onivyde · Topoisomerase I inhibitor (camptothecin prodrug)	NICEUK	Superseded by newer guidance	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexedIrinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer
2005-08-24	Oxaliplatin Eloxatin · Third-generation platinum (DACH-platinum)	NICEUK	Superseded by newer guidance	Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexedAdvanced colorectal cancer (FOLFOX-type regimens)
2005-05-25	Pegylated liposomal doxorubicin Doxil / Caelyx · Cytotoxic (liposomal anthracycline)	NICEUK	Superseded by newer guidance	Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancerAdvanced ovarian cancer after first-line platinum chemotherapy
2003-10-22updated 2016-01-21	Imatinib Gleevec · Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)	NICEUK	Recommended	Guidance on the use of imatinib for chronic myeloid leukaemiaChronic phase CML (first-line)
2003-09-24	Rituximab Rituxan / MabThera (and biosimilars) · Monoclonal antibody (anti-CD20, chimeric)	NICEUK	Recommended	Rituximab for aggressive non-Hodgkin's lymphomaAggressive (diffuse large B-cell) non-Hodgkin lymphoma with CHOP
2002-03-15	Trastuzumab Herceptin (and biosimilars, Phesgo with pertuzumab) · Monoclonal antibody (anti-HER2)	NICEUK	Recommended	Guidance on the use of trastuzumab for the treatment of advanced breast cancerHER2-positive advanced breast cancer
2001-05-08	Gemcitabine Gemzar / Infugem · Nucleoside analogue (deoxycytidine)	NICEUK	Superseded by newer guidance	Guidance on the use of gemcitabine for the treatment of pancreatic cancerAdvanced pancreatic cancer
	5-Aminolevulinic acid (oral, for glioma surgery) Gleolan / Gliolan · Fluorescence-guided surgery agent (protoporphyrin IX precursor)	NICEUK	NICE recommended	NICE searchFluorescence-guided resection of high-grade glioma
	Abemaciclib Verzenio · Small-molecule CDK4/6 inhibitor	SMCScotland	SMC accepted	SMC advice
	Abiraterone acetate Zytiga (generic) · Small-molecule CYP17A1 inhibitor	SMCScotland	SMC accepted	SMC advice
	Acalabrutinib Calquence · Small-molecule covalent BTK inhibitor (second generation)	SMCScotland	SMC accepted	SMC advice
	Afamitresgene autoleucel Tecelra · TCR-T (MAGE-A4)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Afatinib Gilotrif / Giotrif · Small-molecule pan-ErbB TKI (second generation, irreversible)	SMCScotland	SMC accepted	SMC advice
	Aldesleukin (high-dose IL-2) Proleukin · Recombinant interleukin-2 (cytokine)	NICEUK	Not appraised	NICE searchLicensed for metastatic RCC since 1989; largely superseded and rarely used on the NHS. No TA.
	Alectinib Alecensa · Small-molecule kinase inhibitor (ALK)	SMCScotland	SMC accepted	SMC advice
	Alpelisib Piqray · Small-molecule PI3Kα inhibitor	SMCScotland	SMC accepted	SMC advice
	Apalutamide Erleada · Small-molecule AR antagonist	SMCScotland	SMC accepted	SMC advice
	Arsenic trioxide Trisenox · Inorganic arsenical (differentiation agent)	SMCScotland	SMC accepted	SMC advice
	ArteraAI Breast AI digital pathology risk test	NICEUK	Not appraised	NICE searchNot available on the NHS; NICE has assessed AI prognostic tools via early value assessments, not TAs.
	ArteraAI Prostate AI digital pathology prognostic/predictive test	NICEUK	Not appraised	NICE searchNot available on the NHS; NICE early value assessment route applies to digital prognostic tools.
	Asciminib Scemblix · Small-molecule allosteric ABL1 inhibitor (STAMP)	SMCScotland	SMC accepted	SMC advice
	Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) Oncaspar / Asparlas / Rylaze / Erwinaze · Enzyme therapy	SMCScotland	SMC accepted	SMC advice
	Atezolizumab Tecentriq / Tecentriq Hybreza (SC) · Monoclonal antibody (anti-PD-L1)	SMCScotland	SMC accepted	SMC advice
	Avelumab Bavencio · Monoclonal antibody (anti-PD-L1)	SMCScotland	SMC accepted	SMC advice
	Avutometinib + defactinib Avmapki Fakzynja Co-Pack · Small-molecule RAF/MEK clamp + FAK inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Axicabtagene ciloleucel Yescarta · CAR-T (CD19)	SMCScotland	SMC accepted	SMC advice
	Axitinib Inlyta · Small-molecule kinase inhibitor (VEGFR)	SMCScotland	SMC accepted	SMC advice
	Azacitidine Vidaza / Onureg (oral) · Small-molecule hypomethylating agent (cytotoxic)	SMCScotland	SMC accepted	SMC advice
	Belinostat Beleodaq · Pan-HDAC inhibitor (hydroxamate)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Bendamustine Treanda / Bendeka / Belrapzo · Alkylating agent (nitrogen mustard-purine hybrid)	SMCScotland	SMC accepted	SMC advice
	Bevacizumab (glioblastoma use) Avastin · Monoclonal antibody (anti-VEGF)	NICEUK	Not appraised	NICE searchNot licensed for glioblastoma in the EU or UK (EMA refused 2009); not funded on the NHS except via trials or individual funding requests.
	Bicalutamide Casodex · Oral first-generation non-steroidal antiandrogen	NICEUK	Not appraised	NICE searchGeneric; NICE NG131 covers use with GnRH agonists. Funded routinely.
	Binimetinib Mektovi · Small-molecule kinase inhibitor (MEK1/2)	SMCScotland	SMC accepted	SMC advice
	Bleomycin Blenoxane · Glycopeptide antibiotic (DNA-cleaving)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Blinatumomab Blincyto · Bispecific T-cell engager (CD19×CD3)	SMCScotland	SMC accepted	SMC advice
	Bortezomib Velcade · Proteasome inhibitor	SMCScotland	SMC accepted	SMC advice
	Bosutinib Bosulif · Small-molecule BCR-ABL1/SRC TKI	SMCScotland	SMC accepted	SMC advice
	Brentuximab vedotin Adcetris · ADC	SMCScotland	SMC accepted	SMC advice
	Brexucabtagene autoleucel Tecartus · Autologous CD19 CAR-T (CD28 costimulatory domain)	SMCScotland	SMC accepted	SMC advice
	Brigatinib Alunbrig · Small-molecule ALK/EGFR TKI (second generation)	SMCScotland	SMC accepted	SMC advice
	Cabazitaxel Jevtana · Cytotoxic chemotherapy (taxane)	SMCScotland	SMC accepted	SMC advice
	Cabozantinib Cabometyx · Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)	SMCScotland	SMC accepted	SMC advice
	Cadonilimab Kaitanni · Bispecific antibody (PD-1×CTLA-4)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Camizestrant Etcamah · Oral SERD	NICEUK	Appraisal in progress	NICE searchRecently licensed; a NICE appraisal is scheduled or in progress. Interim access may be possible via the CDF interim funding route once NICE issues positive draft guidance.
	Camrelizumab AiRuiKa · Monoclonal antibody (anti-PD-1)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Capmatinib & tepotinib Tabrecta / Tepmetko · Small-molecule kinase inhibitors (MET)	SMCScotland	SMC accepted	SMC advice
	Carboplatin Cytotoxic chemotherapy (platinum)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Carfilzomib Kyprolis · Proteasome inhibitor (irreversible)	SMCScotland	SMC accepted	SMC advice
	Cemiplimab Libtayo · Monoclonal antibody (anti-PD-1)	SMCScotland	SMC accepted	SMC advice
	Ceritinib Zykadia · Small-molecule ALK TKI (second generation)	SMCScotland	SMC accepted	SMC advice
	Cetuximab Erbitux · Monoclonal antibody (anti-EGFR)	SMCScotland	SMC accepted	SMC advice
	Cetuximab sarotalocan Akalux · Photoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye)	NICEUK	Not appraised	NICE searchJapan-only licence (Akalux). Not on the MHRA products register and no NICE guidance or appraisal exists (a NICE search in September 2026 returns nothing). The EMA search page could not be fetched (HTTP 401), so no EU register entry could be confirmed.
	Cisplatin Platinol (generic) · Cytotoxic chemotherapy (platinum)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Cladribine Leustatin / Litak · Purine nucleoside analogue	NICEUK	Not appraised	NICE searchGeneric; standard first-line for hairy cell leukaemia. Funded routinely.
	Cobimetinib Cotellic · Small-molecule kinase inhibitor (MEK1/2)	SMCScotland	SMC accepted	SMC advice
	Cosibelimab Unloxcyt · Anti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	CPX-351 (liposomal daunorubicin-cytarabine) Vyxeos · Liposomal cytotoxic formulation	SMCScotland	SMC accepted	SMC advice
	Crizotinib Xalkori · Small-molecule ALK/ROS1/MET TKI (first generation)	SMCScotland	SMC accepted	SMC advice
	Cyclophosphamide Cytoxan / Endoxan · Alkylating agent (oxazaphosphorine prodrug)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Dabrafenib + trametinib Tafinlar + Mekinist · Small-molecule kinase inhibitors (BRAF + MEK)	SMCScotland	SMC accepted	SMC advice
	Dacomitinib Vizimpro · Small-molecule pan-ErbB TKI (second generation, irreversible)	SMCScotland	SMC accepted	SMC advice
	Dactinomycin (actinomycin D) Cosmegen · Actinomycin antibiotic (transcription inhibitor)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Daratumumab Darzalex / Darzalex Faspro (SC) · Monoclonal antibody (anti-CD38)	SMCScotland	SMC accepted	SMC advice
	Daraxonrasib Rasonque · Small-molecule pan-RAS(ON) inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Darolutamide Nubeqa · Small-molecule AR antagonist	SMCScotland	SMC accepted for other indications; SMC2940 not recommended for darolutamide with ADT in hormone-sensitive metastatic disease	SMC advice
	Dasatinib Sprycel · Small-molecule kinase inhibitor (BCR::ABL1, SRC)	SMCScotland	SMC accepted	SMC advice
	Datopotamab deruxtecan Datroway · ADC	NICEUK	Not appraised	NICE searchNot on the MHRA products register in September 2026 (EU authorisation as Datroway, 4 April 2025, for HR-positive HER2-negative breast cancer after endocrine therapy and chemotherapy). NICE suspended its HR-positive breast cancer appraisal (ID6348) on 16 February 2026 because the company said it would not submit evidence; the NSCLC after platinum appraisal was discontinued, and several other indications are awaiting development.
	Degarelix Firmagon · GnRH antagonist depot	SMCScotland	SMC accepted (restricted)	SMC advice
	Dinutuximab (ch14.18) / dinutuximab beta Unituxin / Qarziba (EU) · Monoclonal antibody (anti-GD2, chimeric)	SMCScotland	SMC accepted	SMC advice
	Disitamab vedotin ADC	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Docetaxel Taxotere (generic) · Cytotoxic chemotherapy (taxane)	NICEUK	Not appraised	NICE searchGeneric; TA101 (2006) recommended docetaxel for metastatic hormone-refractory prostate cancer and it is standard in breast, lung, gastric and head and neck regimens.
	Dordaviprone Modeyso · Small-molecule imipridone (ClpP agonist / DRD2 antagonist)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Dostarlimab Jemperli · Monoclonal antibody (anti-PD-1)	SMCScotland	SMC accepted	SMC advice
	Doxorubicin Adriamycin · Cytotoxic chemotherapy (anthracycline)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Durvalumab Imfinzi · Monoclonal antibody (anti-PD-L1)	SMCScotland	SMC accepted	SMC advice
	Duvelisib Copiktra · Small-molecule PI3Kδ/γ inhibitor	NICEUK	Not appraised	NICE searchEU marketing authorisation application withdrawn; no UK licence. NICE appraisal for relapsed or refractory CLL after 2 or more treatments: TA811 (July 2022), terminated.
	Eflornithine (DFMO) Iwilfin · Small-molecule ornithine decarboxylase inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Enasidenib Idhifa · Small-molecule IDH2 inhibitor	NICEUK	Not appraised	NICE searchEU marketing authorisation application withdrawn 2019; no UK licence.
	Encorafenib Braftovi · Small-molecule kinase inhibitor (BRAF)	SMCScotland	SMC accepted	SMC advice
	Enfortumab vedotin Padcev · ADC	NICEUK	TA page does not name this product	Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)Curated status recommended; the cited TA number may be wrong or renumbered
	Enfortumab vedotin Padcev · ADC	SMCScotland	SMC accepted	SMC advice
	Ensartinib Ensacove · Small-molecule ALK TKI (second generation)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Entrectinib Rozlytrek · Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)	SMCScotland	SMC accepted	SMC advice
	Enzalutamide Xtandi · Small-molecule AR antagonist	SMCScotland	SMC accepted	SMC advice
	Epcoritamab Epkinly · Bispecific T-cell engager (CD20×CD3)	SMCScotland	SMC accepted	SMC advice
	Eribulin Halaven · Synthetic halichondrin B analogue (microtubule dynamics inhibitor)	SMCScotland	SMC accepted	SMC advice
	Erlotinib Tarceva · Small-molecule EGFR TKI (first generation, reversible)	SMCScotland	SMC accepted	SMC advice
	Etoposide VePesid / Etopophos / Toposar · Topoisomerase II inhibitor (podophyllotoxin derivative)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Everolimus Afinitor · Small-molecule mTOR inhibitor	SMCScotland	SMC accepted	SMC advice
	Exemestane Aromasin · Small-molecule steroidal aromatase inactivator	NICEUK	Not appraised	NICE searchGeneric aromatase inhibitor covered by TA112 and NICE NG101; funded routinely.
	Fedratinib Inrebic · Small-molecule JAK2/FLT3 inhibitor	SMCScotland	SMC accepted	SMC advice
	Flotufolastat F-18 Posluma · PET imaging agent	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Fluciclovine F-18 Axumin · PET radiotracer (synthetic amino acid)	NICEUK	Not appraised	NICE searchEU-licensed but not commissioned for routine NHS use; PSMA PET is preferred.
	Fluoroestradiol F-18 (FES PET) Cerianna · PET radiotracer (oestrogen receptor ligand)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Fluorouracil (5-FU) Adrucil / Efudex · Fluoropyrimidine antimetabolite	NICEUK	Not appraised	NICE searchGeneric backbone of colorectal, gastric, pancreatic, breast and head and neck regimens for 60 years; funded routinely. NHS England has required DPYD testing before fluoropyrimidines since 2020.
	FoundationOne CDx / Liquid CDx Comprehensive genomic profiling test	NICEUK	Not appraised	NICE searchNHS England does not commission commercial CGP panels routinely; tumour profiling is delivered by the seven NHS Genomic Laboratory Hubs under the National Genomic Test Directory, including whole genome sequencing for some cancers. Commercial panels may be obtained privately.
	Gallium-68 DOTATATE (and Cu-64 DOTATATE) Netspot / Detectnet · PET radiotracer (somatostatin receptor ligand)	NICEUK	Not appraised	NICE searchSomatostatin receptor PET for neuroendocrine tumours
	Gallium-68 gozetotide (PSMA-11) Illuccix / Gozellix / Locametz · PET imaging agent	NICEUK	Not appraised	NICE searchPSMA PET-CT for prostate cancer staging and recurrence
	Gedatolisib Revtorpyk · Small-molecule pan-PI3K/mTOR inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Gefitinib Iressa · Small-molecule EGFR TKI (first generation, reversible)	SMCScotland	SMC accepted	SMC advice
	Gemcitabine Gemzar / Infugem · Nucleoside analogue (deoxycytidine)	SMCScotland	SMC accepted	SMC advice
	Gemcitabine intravesical system (TAR-200) Inlexzo · Intravesical drug-eluting device	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Gemtuzumab ozogamicin Mylotarg · ADC	SMCScotland	SMC accepted	SMC advice
	Gilteritinib Xospata · Small-molecule kinase inhibitor (FLT3, type I)	SMCScotland	SMC accepted	SMC advice
	Glasdegib Daurismo · Small-molecule smoothened (hedgehog) inhibitor	NICEUK	TA page does not name this product	Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)Curated status recommended; the cited TA number may be wrong or renumbered
	Glasdegib Daurismo · Small-molecule smoothened (hedgehog) inhibitor	SMCScotland	SMC accepted	SMC advice
	Glofitamab Columvi · Bispecific T-cell engager (CD20×CD3, 2:1)	SMCScotland	SMC accepted	SMC advice
	Goserelin / leuprolide (ovarian function suppression) Zoladex; Lupron · GnRH agonist	NICEUK	Not appraised	NICE searchGeneric GnRH agonists; NG101 recommends ovarian function suppression for premenopausal ER-positive breast cancer. Funded routinely.
	Hydroxyurea (hydroxycarbamide) Hydrea / Droxia / Siklos · Oral ribonucleotide reductase inhibitor (cytoreductive)	NICEUK	Not appraised	NICE searchGeneric; first-line cytoreduction in polycythaemia vera and essential thrombocythaemia and used in CML and sickle cell disease. Funded routinely.
	Ibrutinib Imbruvica · Small-molecule covalent BTK inhibitor (first generation)	SMCScotland	SMC accepted	SMC advice
	Idelalisib Zydelig · Small-molecule PI3Kδ inhibitor	SMCScotland	SMC accepted	SMC advice
	Ifosfamide Ifex · Cytotoxic chemotherapy (alkylating agent)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Imatinib Gleevec · Small-molecule kinase inhibitor (BCR-ABL, KIT, PDGFRA)	SMCScotland	SMC accepted	SMC advice
	Imetelstat Rytelo · Telomerase inhibitor (oligonucleotide)	NICEUK	Not appraised	NICE searchNot on the MHRA products register in September 2026 (EU authorisation as Rytelo, 7 March 2025, for transfusion-dependent anaemia in lower-risk MDS after ESA failure). NICE suspended the MDS appraisal (ID3922) on 16 February 2024 while the company confirms its UK regulatory filing plans; myelofibrosis after a JAK inhibitor is awaiting development.
	Inavolisib Itovebi · Small-molecule PI3Kα inhibitor and degrader	NICEUK	Appraisal in progress	NICE searchRecently licensed; a NICE appraisal is scheduled or in progress. Interim access may be possible via the CDF interim funding route once NICE issues positive draft guidance.
	Inotuzumab ozogamicin Besponsa · ADC	SMCScotland	SMC accepted	SMC advice
	Ipilimumab Yervoy · Monoclonal antibody (anti-CTLA-4)	SMCScotland	SMC accepted	SMC advice
	Irinotecan (and liposomal irinotecan) Camptosar / Onivyde · Topoisomerase I inhibitor (camptothecin prodrug)	SMCScotland	SMC accepted	SMC advice
	Isatuximab Sarclisa / Sarclisa Escena (SC) · Monoclonal antibody (anti-CD38)	SMCScotland	SMC accepted	SMC advice
	Ixazomib Ninlaro · Oral proteasome inhibitor (boronate)	SMCScotland	SMC accepted	SMC advice
	Larotrectinib Vitrakvi · Small-molecule pan-TRK inhibitor (first generation)	SMCScotland	SMC accepted	SMC advice
	Lenalidomide Revlimid · Immunomodulatory drug (cereblon E3 ligase modulator)	SMCScotland	SMC accepted	SMC advice
	Lenvatinib Lenvima · Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)	SMCScotland	SMC accepted	SMC advice
	Letrozole (and other aromatase inhibitors) Femara; anastrozole (Arimidex); exemestane (Aromasin) · Small-molecule aromatase inhibitor	SMCScotland	SMC accepted	SMC advice
	Leuprolide (leuprorelin) and GnRH agonists Lupron / Eligard / Camcevi · GnRH agonist depot	NICEUK	Not appraised	NICE searchGeneric and biosimilar GnRH agonists (leuprorelin, goserelin, triptorelin) are the backbone of NHS androgen deprivation; funded routinely without a TA.
	Lifileucel Amtagvi · TIL cell therapy	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Linvoseltamab Lynozyfic · Bispecific T-cell engager (BCMA×CD3)	NICEUK	Appraisal in progress	NICE searchNICE appraisal for relapsed or refractory multiple myeloma after 3 or more treatments (ID6609) is in progress, expected publication 17 February 2027. Not on the MHRA products register in September 2026, so no UK licence could be confirmed.
	Lorlatinib Lorbrena · Small-molecule kinase inhibitor (ALK/ROS1)	SMCScotland	SMC accepted	SMC advice
	Lurbinectedin Zepzelca · Cytotoxic (transcription inhibitor)	NICEUK	Not appraised	NICE searchLicensed in the US and EU but no UK marketing authorisation confirmed; NICE position not yet researched.
	Lutetium-177 dotatate Lutathera · Radioligand therapy (beta)	SMCScotland	SMC accepted	SMC advice
	Lutetium-177 vipivotide tetraxetan Pluvicto · Radioligand therapy (beta)	SMCScotland	SMC not recommended	SMC advice
	Margetuximab Margenza · Fc-engineered monoclonal antibody (anti-HER2)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Melphalan (including hepatic delivery system) Alkeran / Evomela / Hepzato Kit · Alkylating agent (nitrogen mustard)	NICEUK	Not appraised	NICE searchGeneric melphalan is standard for autologous transplant conditioning in myeloma and funded routinely. The Hepzato hepatic delivery system for uveal melanoma liver metastases is not UK-licensed.
	Methotrexate Trexall / Otrexup / Xatmep · Antifolate (DHFR inhibitor)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Midostaurin Rydapt · Small-molecule multikinase inhibitor (FLT3)	SMCScotland	SMC accepted	SMC advice
	Mifamurtide Mepact · Liposomal muramyl tripeptide (macrophage activator)	SMCScotland	SMC accepted	SMC advice
	Mitomycin C Mutamycin / Jelmyto / Zusduri · Alkylating antibiotic (bioreductive)	NICEUK	Not appraised	NICE searchGeneric; intravesical mitomycin is standard after TURBT (NICE NG2). Jelmyto and Zusduri formulations are not UK-licensed.
	Mitotane Lysodren · Adrenolytic agent (DDD derivative)	NICEUK	Not appraised	NICE searchOnly licensed drug for adrenocortical carcinoma; funded routinely without a TA.
	Mosunetuzumab Lunsumio · Bispecific T-cell engager (CD20×CD3)	SMCScotland	SMC accepted	SMC advice
	Nadofaragene firadenovec Adstiladrin · Non-replicating adenoviral gene therapy (intravesical)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Naxitamab Danyelza · Monoclonal antibody (anti-GD2, humanised)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Neratinib Nerlynx · Small-molecule irreversible pan-HER kinase inhibitor	SMCScotland	SMC accepted	SMC advice
	Nilotinib Tasigna · Small-molecule BCR-ABL1 TKI (second generation)	SMCScotland	SMC accepted	SMC advice
	Niraparib Zejula · Small-molecule PARP inhibitor	SMCScotland	SMC accepted	SMC advice
	Nirogacestat Ogsiveo · Small-molecule gamma-secretase inhibitor	NICEUK	Not appraised	NICE searchEU-licensed 2025 for desmoid tumours; UK licence and NICE position not yet researched.
	Nivolumab Opdivo / Opdivo Qvantig (SC) · Monoclonal antibody (anti-PD-1)	SMCScotland	SMC accepted	SMC advice
	Nonavalent HPV vaccine Gardasil 9 · Prophylactic vaccine (virus-like particles)	NICEUK	Not appraised	NICE searchNational HPV vaccination programme
	Obinutuzumab Gazyva · Monoclonal antibody (anti-CD20, glycoengineered type II)	SMCScotland	SMC accepted	SMC advice
	Odronextamab Lynozyfic (EU: Ordspono) · Bispecific T-cell engager (CD20×CD3)	NICEUK	Not appraised	NICE searchNot on the MHRA products register in September 2026; the EU granted a conditional authorisation (Ordspono, 22 August 2024) for relapsed or refractory follicular lymphoma and DLBCL after 2 or more lines. The NICE follicular lymphoma appraisal (ID6726) is awaiting development with no expected date.
	Olaparib Lynparza · Small-molecule PARP inhibitor	SMCScotland	SMC accepted	SMC advice
	Olutasidenib Rezlidhia · Small-molecule IDH1 inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Optune / Optune Pax (TTFields) Optune · Device (tumour treating fields)	NICEUK	Not appraised	NICE searchNICE published a Medtech innovation briefing (MIB) rather than a TA; tumour treating fields are not routinely commissioned by NHS England for glioblastoma. Available privately or via trials.
	Osimertinib Tagrisso · Small-molecule kinase inhibitor (EGFR)	SMCScotland	SMC accepted	SMC advice
	Oxaliplatin Eloxatin · Third-generation platinum (DACH-platinum)	SMCScotland	SMC accepted	SMC advice
	Paclitaxel / nab-paclitaxel Taxol / Abraxane · Cytotoxic chemotherapy (taxane)	SMCScotland	SMC accepted	SMC advice
	Pacritinib Vonjo · Small-molecule JAK2/IRAK1/ACVR1 inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Pafolacianine Cytalux · Folate receptor-targeted near-infrared fluorescent imaging agent	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Palbociclib Ibrance · Small-molecule CDK4/6 inhibitor	SMCScotland	SMC accepted	SMC advice
	Panitumumab Vectibix · Monoclonal antibody (anti-EGFR)	SMCScotland	SMC accepted	SMC advice
	Pazopanib Votrient · Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)	SMCScotland	SMC accepted	SMC advice
	Pegulicianine Lumisight · Protease-activated fluorescent imaging agent	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Pegylated liposomal doxorubicin Doxil / Caelyx · Cytotoxic (liposomal anthracycline)	SMCScotland	SMC accepted	SMC advice
	Pembrolizumab Keytruda / Keytruda Qlex (SC) · Monoclonal antibody (anti-PD-1)	SMCScotland	SMC accepted	SMC advice
	Pemetrexed Alimta (and generics) · Cytotoxic (antifolate)	SMCScotland	SMC accepted	SMC advice
	Pemigatinib Pemazyre · Small-molecule kinase inhibitor (FGFR1-3)	SMCScotland	SMC accepted	SMC advice
	Penpulimab Penpulimab-kcqx · Anti-PD-1 monoclonal antibody (IgG1, Fc-engineered null)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Pertuzumab Perjeta; Phesgo (with trastuzumab, subcutaneous) · Monoclonal antibody (anti-HER2, dimerisation domain)	SMCScotland	SMC accepted	SMC advice
	Pexidartinib Turalio · Small-molecule CSF1R/KIT/FLT3 inhibitor	NICEUK	Not appraised	NICE searchEU marketing authorisation application withdrawn 2020; no UK licence.
	Piflufolastat F-18 / Pylarify TruVu Pylarify · PET imaging agent	NICEUK	Not appraised	NICE searchUS product; UK PSMA PET uses gallium-68 PSMA-11 or F-18 PSMA-1007 supplied by NHS radiopharmacies.
	Pivekimab sunirine Decnupaz · ADC (anti-CD123 antibody, IGN payload)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Polatuzumab vedotin Polivy · ADC	SMCScotland	SMC accepted	SMC advice
	Pomalidomide Pomalyst / Imnovid · Oral cereblon E3 ligase modulator (IMiD)	SMCScotland	SMC accepted	SMC advice
	Ponatinib Iclusig · Small-molecule kinase inhibitor (pan-BCR::ABL1 incl. T315I)	SMCScotland	SMC accepted	SMC advice
	Pralatrexate Folotyn · Antifolate (DHFR inhibitor)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD) Megace; Mirena (IUD) · Hormonal therapy (progestin)	NICEUK	Not appraised	NICE searchGeneric progestins and the levonorgestrel IUD; funded routinely, no TA.
	Pyrotinib Airuini · Small-molecule irreversible pan-HER kinase inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Radioactive iodine (I-131) Sodium iodide I-131 · Radiopharmaceutical (beta/gamma emitter, natural uptake)	NICEUK	Not appraised	NICE searchStandard of care for differentiated thyroid cancer for 80 years; delivered through NHS nuclear medicine departments (BTA guideline). No TA.
	Radium-223 dichloride Xofigo · Targeted alpha therapy (bone-seeking)	SMCScotland	SMC accepted (restricted)	SMC advice
	Regorafenib Stivarga · Small-molecule multi-kinase inhibitor	SMCScotland	SMC accepted	SMC advice
	Relacorilant Lifyorli · Small-molecule glucocorticoid receptor antagonist	NICEUK	Not appraised	NICE searchNot on the MHRA products register in September 2026 and no NICE guidance or appraisal exists (a NICE search returns nothing). The EMA search page could not be fetched (HTTP 401), so any EU application could not be confirmed. Access only through a clinical trial.
	Relatlimab + nivolumab Opdualag · Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)	SMCScotland	SMC accepted	SMC advice
	Repotrectinib Augtyro · Small-molecule kinase inhibitor (ROS1 / NTRK)	NICEUK	Not appraised	NICE searchNot on the MHRA products register in September 2026 (EU conditional authorisation as Augtyro, 13 January 2025, for ROS1-positive NSCLC and NTRK fusion-positive solid tumours). NICE discontinued the ROS1 NSCLC appraisal (ID6277) on 10 February 2026 after hearing nothing further from the company since May 2024, and suspended the NTRK appraisal on 31 March 2025 because the company was no longer pursuing an MHRA marketing authorisation for that indication.
	Retifanlimab Zynyz · Anti-PD-1 monoclonal antibody (IgG4)	NICEUK	Appraisal in progress	NICE searchMHRA-licensed (Zynyz, PL 42338/0024; public assessment report July 2026). NICE is appraising retifanlimab with platinum-based chemotherapy for untreated inoperable, recurrent or metastatic squamous cell anal canal cancer (ID6482, expected publication 16 December 2026). An earlier appraisal for anal canal cancer after platinum chemotherapy (ID3815) was discontinued in December 2022, and NICE has no appraisal for Merkel cell carcinoma. Untreated NSCLC with chemotherapy is in development.
	Revumenib Revuforj · Small-molecule menin inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Ribociclib Kisqali · Small-molecule CDK4/6 inhibitor	SMCScotland	SMC accepted	SMC advice
	Rituximab Rituxan / MabThera (and biosimilars) · Monoclonal antibody (anti-CD20, chimeric)	SMCScotland	SMC accepted	SMC advice
	Romidepsin Istodax · Class I HDAC inhibitor (cyclic peptide)	NICEUK	Not appraised	NICE searchEU licence for PTCL withdrawn; no UK licence.
	Ropeginterferon alfa-2b Besremi · Long-acting mono-pegylated interferon alfa	NICEUK	Appraisal in progress	NICE searchMHRA-licensed (Besremi, PLGB 21344/0026-0027). The NICE appraisal for polycythaemia vera without symptomatic splenomegaly (ID1596) has been listed as in progress since scoping in May 2019 with no expected publication date, so there is no NICE recommendation; funding is by local decision or individual funding request.
	Rucaparib Rubraca · Small-molecule PARP inhibitor	SMCScotland	SMC accepted	SMC advice
	Rusfertide Mimrylo · Hepcidin mimetic peptide	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Ruxolitinib Jakafi / Jakavi · Small-molecule JAK1/JAK2 inhibitor	SMCScotland	SMC accepted	SMC advice
	Sacituzumab govitecan Trodelvy · ADC	SMCScotland	SMC accepted	SMC advice
	Satricabtagene autoleucel CAR-T (Claudin 18.2)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Selpercatinib Retevmo · Small-molecule kinase inhibitor (RET)	SMCScotland	SMC accepted	SMC advice
	Sevabertinib Hyrnuo · Small-molecule kinase inhibitor (HER2)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Shield Blood-based colorectal cancer screening test	NICEUK	Not appraised	NICE searchUS-only blood-based colorectal screening test; NHS bowel screening uses the FIT stool test.
	Somatostatin analogues (octreotide, lanreotide) Sandostatin LAR, Somatuline Depot · Peptide hormone analogue (SSTR2 agonist)	NICEUK	Not appraised	NICE searchOctreotide and lanreotide are long-established for functional NET symptoms and tumour control (CLARINET, PROMID); funded routinely without a TA.
	Sonidegib Odomzo · Small-molecule smoothened inhibitor	NICEUK	Not appraised	NICE searchLocally advanced basal cell carcinoma not amenable to curative surgery or radiotherapy
	Sonrotoclax Beqalzi · Small-molecule BCL-2 inhibitor (second generation)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Sorafenib Nexavar · Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)	SMCScotland	SMC accepted	SMC advice
	Sotorasib Lumakras · Small-molecule inhibitor (KRAS G12C)	SMCScotland	SMC accepted	SMC advice
	Sunitinib Sutent · Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)	SMCScotland	SMC accepted	SMC advice
	Sunvozertinib Zegfrovy · Small-molecule EGFR exon 20 insertion TKI (irreversible)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Taletrectinib Ibtrozi · Small-molecule ROS1 TKI (next generation, CNS-penetrant)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Talimogene laherparepvec Imlygic · Oncolytic virus (HSV-1)	SMCScotland	SMC accepted (restricted)	SMC advice
	Tamoxifen Nolvadex · Small-molecule SERM	NICEUK	Not appraised	NICE searchGeneric; recommended in NICE NG101 for ER-positive breast cancer and for risk reduction in high-risk women (CG164). Funded routinely.
	Tebentafusp Kimmtrak · ImmTAC (TCR×CD3 bispecific)	SMCScotland	SMC accepted	SMC advice
	Technetium-99m tilmanocept Lymphoseek · Radiopharmaceutical lymphatic mapping agent	NICEUK	Not appraised	NICE searchEU-licensed sentinel node tracer; NHS sentinel node biopsy mostly uses Tc-99m nanocolloid. No TA.
	Telisotuzumab vedotin Emrelis · ADC	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Thalidomide Thalomid · Oral cereblon modulator (first IMiD)	SMCScotland	SMC accepted	SMC advice
	Tisagenlecleucel Kymriah · CAR-T (CD19)	SMCScotland	SMC accepted	SMC advice
	Tivozanib Fotivda · Small-molecule kinase inhibitor (VEGFR)	SMCScotland	SMC accepted	SMC advice
	Topotecan Hycamtin · Cytotoxic (topoisomerase-I inhibitor)	SMCScotland	SMC accepted	SMC advice
	Toripalimab Loqtorzi · Monoclonal antibody (anti-PD-1)	NICEUK	Appraisal in progress	NICE searchMHRA-licensed (Loqtorzi, PL 60874/0001). NICE is appraising toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer (ID6406): draft guidance consultation 27 August to 18 September 2026, second committee meeting 4 November 2026, expected publication 13 January 2027. The oesophageal squamous cell cancer appraisal (TA1024, December 2024) was terminated after Shanghai Junshi Bioscience asked to delay its evidence submission.
	Tovorafenib Ojemda · Small-molecule type II RAF inhibitor	NICEUK	Appraisal in progress	NICE searchNICE appraisal for relapsed or refractory paediatric low-grade glioma with a BRAF fusion, rearrangement or V600 mutation in people aged 6 months and over (ID6557) is in progress with no expected date (scoping consultation July 2025). Not on the MHRA products register in September 2026; the EU granted a conditional authorisation (Ojemda) on 20 April 2026.
	Trabectedin Yondelis · Cytotoxic (DNA minor-groove binder)	SMCScotland	SMC accepted	SMC advice
	Trastuzumab Herceptin (and biosimilars, Phesgo with pertuzumab) · Monoclonal antibody (anti-HER2)	SMCScotland	SMC accepted	SMC advice
	Trastuzumab biosimilars Ogivri, Herzuma, Kanjinti, Trazimera, Ontruzant, Hercessi · Biosimilar monoclonal antibody (anti-HER2)	NICEUK	Not appraised	NICE searchBiosimilars are not appraised separately: they fall under the originator's TAs (TA34, TA107, TA208). NHS England's biosimilar commissioning framework drove rapid switching from 2018.
	Trastuzumab deruxtecan Enhertu · ADC	SMCScotland	SMC accepted	SMC advice
	Trastuzumab emtansine Kadcyla · ADC	SMCScotland	SMC accepted	SMC advice
	Trastuzumab rezetecan ADC	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Tremelimumab Imjudo · Monoclonal antibody (anti-CTLA-4)	SMCScotland	SMC accepted	SMC advice
	Tretinoin (all-trans retinoic acid, ATRA) Vesanoid · Oral retinoid (differentiation agent)	NICEUK	Not appraised	NICE searchStandard for APL with arsenic trioxide (TA526) or chemotherapy; funded routinely without its own TA.
	Trifluridine/tipiracil Lonsurf · Cytotoxic chemotherapy (oral nucleoside)	SMCScotland	SMC accepted	SMC advice
	Tucatinib Tukysa · Small-molecule kinase inhibitor (HER2)	SMCScotland	SMC accepted	SMC advice
	Vemurafenib Zelboraf · Small-molecule kinase inhibitor (BRAF V600)	SMCScotland	SMC accepted	SMC advice
	Venetoclax Venclexta · Small-molecule BCL-2 inhibitor	SMCScotland	SMC accepted	SMC advice
	Vepdegestrant Veppanu · PROTAC oestrogen receptor degrader	NICEUK	Appraisal in progress	NICE searchRecently licensed; a NICE appraisal is scheduled or in progress. Interim access may be possible via the CDF interim funding route once NICE issues positive draft guidance.
	Vimseltinib Romvimza · Small-molecule kinase inhibitor (CSF1R)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Vinblastine Velban · Vinca alkaloid (microtubule inhibitor)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Vincristine Oncovin / Marqibo · Vinca alkaloid (microtubule inhibitor)	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Vinorelbine Navelbine · Semi-synthetic vinca alkaloid	NICEUK	Not appraised	NICE searchLong-established generic: never subject to a technology appraisal; funded routinely through hospital formularies and NHS England systemic anti-cancer therapy protocols.
	Vusolimogene oderparepvec Tudriqev · Oncolytic virus (HSV-1)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Zanubrutinib Brukinsa · Small-molecule covalent BTK inhibitor (second generation)	SMCScotland	SMC accepted	SMC advice
	Zenocutuzumab Bizengri · Bispecific antibody (HER2×HER3)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Zidesamtinib Jideytro · Small-molecule kinase inhibitor (ROS1)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Ziftomenib Komzifti · Small-molecule menin inhibitor	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
	Zongertinib Hernexeos · Small-molecule kinase inhibitor (HER2)	NICEUK	Not appraised	NICE searchNo UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.

What each body decides

NICE (England and Wales) publishes technology appraisals: recommended, recommended with restrictions (optimised), managed access through the Cancer Drugs Fund, or not recommended. A positive appraisal obliges the NHS to fund the medicine within 90 days. SMC does the same for Scotland.

G-BA (Germany) runs the early benefit assessment after launch: the medicine is reimbursed from day one and the verdict (added benefit: major, considerable, minor, non-quantifiable, none) sets the price negotiation. The register here shows procedures and their status; the benefit category is on the linked page.

PBAC (Australia) recommends whether a medicine is listed on the Pharmaceutical Benefits Scheme. Outcomes are published per meeting as a document; open it for the product-level recommendation.

France (HAS) and Canada (CDA-AMC) are not fetched: neither publishes a list a script can read without a key or a browser. Their verdicts belong in the product record when sourced by hand.

How this table is built

National Institute for Health and Care Excellence (United Kingdom (England and Wales)): Each TA cited in coverage-uk.ts is fetched to confirm title, publication date and withdrawal status. 182/182 requests succeeded.
Gemeinsamer Bundesausschuss (Germany): First 8 pages of the early benefit assessment register, matched to corpus products by active substance. 8/8 requests succeeded.
Pharmaceutical Benefits Advisory Committee (Australia): Latest meetings listed with links to the outcome documents (PDF; verdicts not extracted). 1/1 requests succeeded; 6 most recent meetings listed.
Curated NICE outcomes and SMC positions come from the hand-researched UK coverage table and appear when there is no TA page to verify.
Fetched 2026-10-01; refreshed monthly by GitHub Actions. Status on when each feed last ran.

For what the verdict means to a patient’s bill, see paying for care in the US (Medicare part, prior authorisation and manufacturer assistance programmes) and what the NHS offers.